University of Vermont

UVM ScholarWorks
Graduate College Dissertations and Theses

Dissertations and Theses

2019

Maintenance Of Mammary Epithelial Phenotype By Transcription
Factor Runx1 Through Mitotic Gene Bookmarking
Joshua Rose
University of Vermont

Follow this and additional works at: https://scholarworks.uvm.edu/graddis
Part of the Biochemistry Commons, and the Genetics and Genomics Commons

Recommended Citation
Rose, Joshua, "Maintenance Of Mammary Epithelial Phenotype By Transcription Factor Runx1 Through
Mitotic Gene Bookmarking" (2019). Graduate College Dissertations and Theses. 998.
https://scholarworks.uvm.edu/graddis/998

This Thesis is brought to you for free and open access by the Dissertations and Theses at UVM ScholarWorks. It
has been accepted for inclusion in Graduate College Dissertations and Theses by an authorized administrator of
UVM ScholarWorks. For more information, please contact scholarworks@uvm.edu.

MAINTENANCE OF MAMMARY EPITHELIAL PHENOTYPE BY
TRANSCRIPTION FACTOR RUNX1 THROUGH MITOTIC GENE
BOOKMARKING

A Thesis Presented

by
Joshua Rose
to
The Faculty of the Graduate College
of
The University of Vermont

In Partial Fulfillment of the Requirements
for the Degree of Master of Science
Specializing in Cellular, Molecular, and Biomedical Sciences
January, 2019

Defense Date: November 12, 2018
Thesis Examination Committee:
Sayyed Kaleem Zaidi, Ph.D., Advisor
Gary Stein, Ph.D., Advisor
Seth Frietze, Ph.D., Chairperson
Janet Stein, Ph.D.
Jonathan Gordon, Ph.D.
Cynthia J. Forehand, Ph.D. Dean of the Graduate College

ABSTRACT

Breast cancer arises from a series of acquired mutations that disrupt normal
mammary epithelial homeostasis and create multi-potent cancer stem cells that can
differentiate into clinically distinct breast cancer subtypes. Despite improved therapies
and advances in early detection, breast cancer remains the leading diagnosed cancer in
women.
A predominant mechanism initiating invasion and migration for a variety of
cancers including breast, is epithelial-to-mesenchymal transition (EMT). EMT— a
trans-differentiation process through which mammary epithelial cells acquire a more
aggressive mesenchymal phenotype—is a regulated process during early mammary
gland development and involves many transcription factors involved in cell lineage
commitment, proliferation, and growth. Despite accumulating evidence for a broad
understanding of EMT regulation, the mechanism(s) by which mammary epithelial
cells maintain their phenotype is unknown.
Mitotic gene bookmarking, i.e., transcription factor binding to target genes
during mitosis for post mitotic regulation, is a key epigenetic mechanism to convey
regulatory information for cell proliferation, growth, and identity through successive
cell divisions. Many phenotypic transcription factors, including the hematopoietic Runt
Related Transcription Factor 1 (RUNX1/AML1), bookmark target genes during
mitosis. Despite growing evidence, a role for mitotic gene bookmarking in maintaining
mammary epithelial phenotype has not been investigated.
RUNX1 has been recently identified to play key roles in breast cancer
development and progression. Importantly, RUNX1 stabilizes the normal breast
epithelial phenotype and prevents EMT through repression of EMT-initiating pathways
[9]. Findings reported in this thesis demonstrate that RUNX1 mitotically bookmarks
both RNA Pol I and II transcribed genes involved in proliferation, growth, and
mammary epithelial phenotype maintenance. Inhibition of RUNX1 DNA binding by a
specific small molecule inhibitor led to phenotypic changes, apoptosis, differences in
global protein synthesis, and differential expression of ribosomal RNA as well as
protein coding genes and long non-coding RNA genes involved in cellular phenotype.
Together these findings reveal a novel epigenetic regulatory role of RUNX1 in normallike breast epithelial cells and strongly suggest that mitotic bookmarking of target genes
by RUNX1 is required to maintain breast epithelial phenotype. Disruption of RUNX1
bookmarking results in initiation of epithelial to mesenchymal transition, an essential
first step in the onset of breast cancer.
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CHAPTER 1: BREAST CANCER
1.1. Overview
Breast cancer arises from a series of acquired mutations that lead to a clonal
expansion of cells that disrupt normal mammary homeostasis. According to recent
statistics, one out of eight women will develop invasive breast cancer over the course of
her lifetime [10]. Breast cancer is the most common cancer among women and the
second most common cause of cancer-related death in women [11, 12]. Incidence of
breast cancer appears to remain unchanged within the past few decades, however, death
rate from breast cancer has actually decreased [13]. This is thought to be from
improved technologies for earlier detection and better practices in breast cancer
screening, rather than from improved therapies. Five-year survival rates between 20072013 reflect this, as patients staged with localized breast cancer at diagnosis have a
99% five-year survival, whereas distant (metastatic) staged breast cancer at diagnosis
only has 27% five-year survival [13]. The total number of expected deaths in the
United States due to breast cancer in 2017 were around 40,000 [12]. To further reduce
the number of breast cancer related deaths in women, the mechanisms of breast cancer
onset and progression need to be better understood.

1.2. Clinical Distinctions of Breast Cancer
Breast cancer tumors are traditionally classified based on morphologic features
and further classified by tumor size, tumor grade, lymph node involvement, margin
status, and lymph vascular invasion (Fig. 1) [14-16]. Clinically predictive biological
1

markers used in breast cancer diagnosis are estrogen receptor (ER), progesterone receptor
(PR), and Her-2/neu receptor status (HER-2) [17]. Further subtype classification can be
described by the molecular makeup of the tumor: ER+ (luminal A or B), ER- (Her-2/neu,
triple negative, normal breast-like) [18-20].

Figure 1 The different intrinsic subtypes of breast cancer. From Dai X, et al 2015 [3]

Luminal A tumors are the largest constituent of breast cancers, making up about
60% of total breast cancers [15]. They are primarily characterized by an increased
expression of ESR-1 (estrogen receptor gene), GATA3, FOXA1, and LIV1 as well as a
lack of expression of Her-2/neu [14]. Luminal A ER+ tumors have a higher recurrencefree survival and superior survival outcome compared to other tumor types [15, 20-23].
Luminal B tumors are characterized by higher expression of ESR-1, cytokeratins
(CK8/18), and genes associated with proliferation such as CCNB1, MYBL2, and MKI67
[19]. Luminal B tumors can be further classified into Her-2/neu positive or negative. In
comparison to luminal A tumors, luminal B tumors are more heterogeneous in their
2

molecular makeup, have higher proliferation rates, and tend to have worse clinical
outcomes and chances of relapse [15, 21, 23, 24].
Constituting about 15% of total breast cancer tumors are HER-2 enriched
subtype classifications. Similar in makeup to luminal B tumors, these are ER- and
defined by a molecular makeup of increased HER-2/Neu gene expression, genes
associated with proliferation, and specific genes related to HER-2/Neu: GRB7 and
TRAP100 [14]. About 40% of HER-2/Neu enriched tumor subtypes also possess
mutations involving TP53. HER-2/Neu tumors tend to behave more aggressively and
therefore respond better to chemotherapeutic treatments [25-27]. These tumors have a
higher percent chance of local recurrence in comparison to luminal A subtypes and are
commonly seen to metastasize to bone and liver [28, 29].
Basal-like tumors (triple negative, i.e., negative for ER, PR, and HER-2) can be
classified by an ER- status, a decrease in gene expression related to ER and HER-2/Neu.
Additionally, these tumors are also classified with an upregulation of KRT5, KRT17,
CX3CL1, ANXA8, and TRIM29, genes pertaining to basal cell phenotype. Additionally, it
is estimated that about 75% of tumors classified by basal-like subtype possess mutations
in TP53 [14]. Epidermal growth factor receptor (EGFR) levels are also increased in
basal-like tumors. In comparison to luminal subtypes, basal-like tumors have a worse
prognosis, shorter relapse-free survival, and an increase in metastases to the central
nervous system [29].
In addition to the well-established subtypes discussed above, lesser-known
subtypes of breast carcinoma have also been defined. Of these, claudin low subtypes are
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perhaps the most well defined [14]. These subtypes closely resemble basal-like tumor
subtypes but also have lower levels of both proliferative genes and the cytokeratins that
are commonly expressed in basal-like tumor subtypes. A distinguishing feature of claudin
low subtypes is higher expression of genes involved in other cellular processes
contributing to cancer phenotypes, such as cell-cell communication, differentiation, and
angiogenesis. Interestingly, genes primarily involved in the immune system are also
overexpressed, while genes involved in cell-cell adhesion have decreased expression.
This aspect is how the claudin subtype received its name; decreased expression of claudin
genes along with E cadherin [14, 30].
Another lesser known molecular apocrine subtype has been previously identified
[31]. This tumor subtype is ER- with overexpression of ERRB2 gene and an increase in
androgen receptor signaling. ERRB2 gene encodes a receptor tyrosine kinase that is
thought to both stabilize and alter androgen receptor function as a result from
overexpression studies [32]. Lastly, the most recently suggested subtype of breast
carcinomas is the interferon-related group subtype. The classification comes from breast
tumors that emphasize higher expression of genes involved in proliferation and those
related to interferons, specifically STAT1 [33, 34]. Involvement of immune-related
processes may play a role in the formation of favorable tumor microenvironments,
therefore exacerbating cancer growth.

1.3. Cellular Models for Investigating Breast Cancer
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There are currently 73 cell lines and hybridoma’s available on ATCC ® and
documented in Cancer Cell Line Encyclopedia (CCLE – Broad/Novartis) originating
from humans that are related to and used in breast cancer research. Depending on the
purpose of experimentation, different breast cancer cell lines have been developed to
explore targeted areas of breast cancer (Fig. 2). For example, MDA-MB-231 is a breast
epithelial cell line derived from human mammary gland/breast with breast
adenocarcinoma. This cell line exhibits metastatic behavior and is suitable for exploring
molecular mechanisms of metastasis in breast epithelial cells [35, 36]. Another model of

Figure 2. Cell line subtypes for investigating breast cancer. Figure adapted from Dai X, et al 2017 [5]

5

tumor subtypes are MCF-7 cells [37]. These cells are also an epithelial cell line derived
from human mammary gland/breast tissue that express estrogen receptor as well as the
WNT7B oncogene, making this cell line a suitable model for exploring responses to
hormone-based therapies at an in vitro level [38].
One other model of tumor subtypes is the MCF10 series of cell lines. First
isolated from a 36 year old Caucasian woman with benign fibrocystic disease, a nontumorigenic breast epithelial cell line termed MCF10A cells were isolated for culture
[39]. These cells spontaneously immortalized and serve as a suitable model for exploring
normal-like breast epithelial phenotype and the beginning of cancer formation.
Transcriptional profiling of various breast cancers revealed subtypes that closely
resembled normal epithelial-like breast cells, which suggests that the biology and
phenotype of MCF10A cells are ideal for further understanding the initiating events of
breast cancer onset and progression [18, 19, 40]. To develop a cell-based model for breast
cancer progression, MCF10A cells were overexpressed with oncogenic H-Ras to create a
premalignant breast epithelial cell line termed MCF10-AT1 [41]. Repeated subcutaneous
injection and harvest of MCF10AT1 cells in mice was used to generate the MCF10-CA1a
cell line [42]. Repeated passage and harvest of these cells in mice yielded a new
aggressive phenotype due to transformation. MCF10-CA1a cells exhibit the highest
degree of metastasis and cell proliferation in comparison to MCF10A and MCF10AT1,
making them a suitable model to study the molecular mechanisms underlying the
advanced stage breast cancer. Importantly, the three cell lines have near normal
karyotype, making them ideal for studies examining changes in higher order genome
6

organization. Taken together, these three cell lines are a powerful cellular model for
discovering the molecular mechanisms driving breast cancer progression from a normal,
epithelial-like phenotype (MCF10A), premalignant phenotype (MCF10AT1), and a
metastatic/aggressive phenotype (MCF10A-CA1a).

1.4. Normal Mammary Gland Development
The mammary gland is a dynamically changing organ dependent upon hormonal
cues in women. Changes that arise after proper development of the mammary gland
utilize cell-fate specification and cell differentiation pathways that are vital for tissue
remodeling. In breast cancer, these pathways are dysregulated and are therefore
informative to understand the onset and progression of breast cancer.
Mammary gland development initiates in a developing embryo. Developmental
studies in mice indicate the presence of early mammary gland lines starting at embryonic
day 10.5 and further progressing into more differentiated mammary mesenchyme by day
13.5 with a fat pad mesenchyme forming at day 14.5 [1, 43-45]. Epithelial cells
overlaying the mesenchyme form the nipple and form the beginnings of a ductal tree
underneath the nipple at day 18.5 [44, 46]. Following embryonic development, mammary
epithelial cells near the nipple remain quiescent. It is during puberty where hormonal
cues are sensed by mammary epithelial cells and they invade the fat pad. The invading
branch is made up of epithelial cells, where leading cells of the branch are comprised of
epithelial cells that exhibit mesenchymal-like behavior, suggesting that regulated
epithelial-to-mesenchymal transition (EMT) plays a role in this invasion process [47-50].
7

Inactivation of this branching isn’t entirely understood, although endogenous production
of transforming growth factor beta (TGFβ) and mechanical sensing of the tissue
microenvironment have been shown to play roles [48]. A more finalized glandular
structure consisting of a bilayer of epithelial cells (luminal and myoepithelial cells) upon
inactivation of the branching takes shape and is referred to as the virgin mammary gland.
The mammary gland undergoes further changes later during estrus cycles and pregnancy,

Figure 3. Mammary gland development. Figure from Inman
JL, et al 2015. [1]

eventually leading to the involution of the gland and a return to a pre-pregnant state
through tissue remodeling programs [1, 51, 52].
Various types of epithelial cells make up the fully formed and developed adult
mammary gland (Fig. 3). Briefly summarized, the ducts throughout the mammary gland
8

are oriented in apical fashion with epithelial bilayer lining either side of a duct. The
bilayer has luminal epithelial cells in contact with the lumen of the duct and a
myoepithelial cell layer that is in contact with the basement membrane of surrounding
breast tissue. Luminal cells are terminally differentiated during pregnancy to produce and
secrete milk proteins into the duct and, when coupled with contraction of myoepithelial
cells, milk is released from the mammary gland [53, 54]. These cells receive hormonal
and other cues that triggers further development and tissue remodeling in a regulated
fashion when necessary, i.e. during postnatal development, pregnancy.
There are molecular mechanisms in place that commit epithelial cells in the
mammary gland to remain differentiated epithelial cells, yet this is still largely an
unanswered and compelling question. During events such as pregnancy, where the
mammary gland receives an influx of ovarian steroid hormones such as estrogen and
progesterone, the mechanisms that regulate controlled differentiation and commitment to
an epithelial lineage are altered in a tightly regulated manner to facilitate a new
proliferative phenotype for the cells. During cancer onset, these regulated differentiation
processes appear to be perturbed.
Mammary epithelial cells respond to estrogen through estrogen receptor α (ERα)
activity and progesterone through progesterone receptor (PR) activity. Upon ligand
binding, these receptors translocate into the nucleus, where the receptor binds to target
genes and can recruit co-activating or co-repressing proteins. These steroid hormone
receptors also have effects on one another, as ERα activity also increases PR activity, yet
how hormone receptor activities influence one another are still being understood [55-57].
9

Epithelial cells that are ER+ act in a paracrine fashion by acting on nearby/adjacent
epithelial cells to initiate a proliferative phenotype which facilitates further expansion and
ductal invasion; this paracrine activation is required for ductal expansion [58-60]. As a
result of the ERα activity, ER+ cells release epidermal growth factor (EGF), transforming
growth factor alpha (TGFα), and amphiregulin, all of which are required for ductal
expansion [55, 61-63]. Progesterone-activated mediators that play a role in progesteroneinduced proliferation include RANKL, WNT-4, and Cyclin D1 [64-66]. These hormonedriven mechanisms trigger expansion of mammary ducts through an increase in epithelial
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cell proliferation, however there are additional mechanisms that regulate and control
mammary epithelial cell differentiation.
The activities of different transcription factors in mammary epithelial cells play
important roles in determining cell lineage commitment and cell fate (Fig. 4). For
example, GATA3 is expressed in luminal epithelial cells and is important for directing
luminal epithelial cell differentiation [67]. This differentiation is achieved through
GATA3 acting upon FOXA1, a pioneer transcription factor which mediates ERα
expression [68]. By altering ERα expression, it also inherently affects the paracrine

Figure 4. ER and PR signaling pathways in breast epithelial cells.
Figure from Tanos T, et al 2012. [6]
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mediators released from ER-responsive epithelial cells, perhaps providing phenotypic
transcription factors a more important role for dictating differentiation and cell lineage
commitment in mammary tissue. Another transcription factor shown to be important in
luminal epithelial cell expansion is CCAAT/Enhancer Binding Protein Beta (C/EBPβ).
PR levels in mammary glands of C/EBPβ -/- mice were elevated while lobuloalveolar
development was inhibited, indicating PR is parallel or downstream of C/EBPβ [69].
Other transcription factors that act downstream of estrogen and progesterone
activity are also important in cell fate determination and lineage commitment. For
example, STAT5a is important for glandular development during pregnancy, and the
phosphorylated form of STAT5a (p-STAT5a) is required for branching and proliferation
of the mammary gland [70-72]. Both PR and ERα regulate STAT5a expression [73].
E74-like factor 5 (Elf5) is yet another transcription factor involved in epithelial cell
differentiation (specifically alveolar cells). RANKL is shown to regulate Elf5 levels, and
RANKL is regulated by progesterone receptor activity [74, 75]. These transcription
factors play roles in determining cell fate upstream and downstream of ERα and PR
activity.
Deregulation of differentiation processes operative in mammary epithelial cells
can lead to uncontrolled proliferation and potentially breast cancer formation. The
traditional view of breast cancer onset and progression into various subtypes stems from
the different epithelial cells present in the mammary gland (luminal and basal). Insults to
the DNA in these cells leads to mutations that result in a multi-potent cell capable of
initiating tumor growth [76]. These insults could alter known oncogenes to facilitate
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uncontrolled growth, tumor suppressor genes to prevent the suppression of
proliferation/growth, as well as disrupt genes involved in mammary developmental
processes. Cells of the primary tumor in certain breast cancer subtypes often mimic the
originating epithelial cell lineage where the insult occurred [77]. However, this is not
always the case, as more recent studies show that it is possible to generate multiple
subtypes from a single lineage [78]. Importantly, epigenetic mechanisms also facilitate
various aspects of breast cancer formation and progression, however are not quite as well
understood. The fundamental aspect of breast cancer formation is that mammary
epithelial cells differentiate from their intended tissue-specific function, i.e. lose
epithelial phenotype, and give rise to a multi-potent cell. There are mechanisms in place
for mammary epithelial cells to maintain their epithelial phenotype, but how these
mechanisms stabilize the epithelial phenotype is not well understood.
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CHAPTER 2: EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT)
2.1. Biological Process of EMT
Little is known regarding the precise mechanisms by which normal mammary
epithelial cell structure and function are maintained and protected from transitioning into
a more malignant and cancer-like phenotype through epithelial-to-mesenchymal

Figure 5. Overview of EMT and MET. Figure from Lamouille, Xu, and Derynck
2014. [2]

transition (EMT) (Fig. 5). Pathways and proteins involved in EMT sheds significant
insight into the mechanisms that govern mammary epithelial cell maintenance.
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EMT is an essential physiological process that allows a polarized epithelial cell to
undergo a series of biochemical changes and assume a more mesenchymal-like
phenotype, i.e. enhanced migratory capacity, invasiveness, resistance to apoptosis, and
increased production of extracellular matrix (ECM) components [79, 80]. EMT was first
identified as a vital process in embryonic development, specifically during gastrulation
[81, 82]. Subsequent research and increased understanding of EMT now supports a model
of three separate types of EMT. The first type of EMT is associated with implantation,
embryo formation, and organ development where these EMTs produce cells with
mesenchymal-like phenotypes that lack invasive properties [80, 83]. The second type of
EMTs associate with tissue regeneration, wound healing, and organ fibrosis; this type of
EMT is tightly coordinated with inflammatory responses. The third type of EMT is
associated with cancer formation. Briefly, oncogenes and tumor suppressors hijack
mechanisms underlying EMT to facilitate clonal expansion of a plastic cell that often
metastasizes to a new tissue after acquiring more mesenchymal-like phenotypes.
However, this third type of EMT also produces a spectrum of cells with both epithelial
and mesenchymal-like traits rather than strictly epithelial or mesenchymal phenotype [80,
84]. For a cell to metastasize (which most likely possesses more mesenchymal traits),
invade, and seed secondary tumor growth resembling the primary tumor at a distant site,
the cell must undergo mesenchymal-to-epithelial transition (MET). Type 3 EMT,
involved in cancer metastasis and tumor formation, has been challenging to study
because of the plasticity of affected cells to undergo MET. However, there is
considerable evidence illustrating the various factors involved in this process.
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Under normal circumstances, EMT is a tightly controlled and regulated process
involving cross talk between transcription factors, signaling pathways, and miRNAs.
Transcription factors that include twist basic helix-loop-helix transcription factor 1
(TWIST1), snail family zinc finger 1 (SNAI1), snail family zinc finger 2 (SNAI2/SLUG),
zinc finger E-box binding homeobox 1 (ZEB1), and fork head box C2 (FOXC2) [85-87]
are primarily responsible for inducing EMT. These transcription factors and their activity
are mediated by transforming growth factor beta (TGFβ), epidermal growth factor (EGF),
fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), Wnt, Sonic
Hedgehog (Shh), Notch, and integrin signaling pathways [84, 88-93]. Loss of epithelial
cadherin (E-Cad) and β-catenin (cellular adhesion molecules) are an established hallmark
of EMT initiation. Following induction of EMT, it is also possible that signals from
tumor microenvironments influence expression of specific EMT transcription factors.
Another layer of regulatory complexity is provided by various epigenetic mechanisms,
i.e. heritable alterations in gene expression without changes in DNA sequence, that
contribute to EMT and cancer progression. These epigenetic mechanisms include global
DNA hypomethylation, gene promoter hypermethylation, histone modification,
deregulation of chromatin remodeling complexes, and deregulation of important micro
RNAs (miRNAs) (Reviewed in [86]). Despite the breadth of knowledge regarding EMT,
a more fundamental understanding of breast epithelial cell maintenance is lacking, i.e.,
how does a mammary epithelial cell remain an epithelial cell through successive cell
divisions, and prevents processes like EMT, tumor formation, and cancer metastasis?
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CHAPTER 3: MITOTIC GENE BOOKMARKING
3.1. Phenotypic Transcription Factors Maintain Cellular Phenotype
Each cell lineage arises from multipotent stem cell, capable of differentiating
into committed cells in a context dependent function. Committed cells must maintain
their identity through successive cell divisions. Phenotypic transcription factors are
responsible for controlling gene expression and maintaining cellular identity in tissuespecific contexts, however the precise mechanisms are not well understood.

Figure 6. Mitotic retention of transcription factors on chromatin, with highlighted differences in
signal of RNA Pol I vs II transcribed genes. Figure adapted from Zaidi SK, et al. 2011 [8]

Mitotic gene bookmarking is defined as the retention of key regulatory proteins
that include sequence specific transcription factors, chromatin modifying factors and
components of RNA Pol I and II regulatory machineries at gene loci on mitotic
chromosomes (Fig. 6). For cells to remain committed to their differentiated phenotype,
cells must maintain this identity through successive cell divisions. By bookmarking target
genes during mitosis, regulatory proteins such as phenotypic transcription factors ensure
that genes important for the cellular phenotype will be expressed in progeny cells
immediately completing mitosis. In addition to phenotypic transcription factors,
17

chromatin modifiers/histone variants and functional components of RNA Pol I and II
machineries also bookmark genes during mitosis. With these three classes of proteins
mitotically bookmarking genes during mitosis, coordinated control of cell phenotype,
growth, and proliferation are ensured. Importantly, mitotic gene bookmarking has
recently been implicated in maintenance of tumor/cancer phenotype [7].

3.2. Timeline of Mitotic Gene Bookmarking
Mitotic gene bookmarking was first described in 1997 by Levens et al. [94].
These authors demonstrated that chromatin conformation was distorted specifically at
transcription start sites (TSS) of genes poised for reactivation after successful completion
of mitosis. They postulated that, in order for proper chromatin reassembly following
mitosis, a subset of factors remain bound to mitotic chromosomes at these loci, thus
providing a “molecular bookmark”. A review from a separate group (John and Workman)
in 1998 supported the bookmarking hypothesis as a “mechanism by which transcriptional
competence can be maintained through mitosis” [95]. Challenging this idea, another
research group demonstrated that condensed chromatin structure during mitosis led to the
displacement of different sequence-specific transcription factors [96]. The first evidence
of mitotic bookmarking by a transcription factor was reported in 2003 by our group [97].
The sequence-specific phenotypic transcription factor RUNX2 was shown by in situ
immunofluorescence to remain associated with chromatin throughout mitosis. Each
progeny nuclei possessed equivalent levels of Runx2 protein following division and was
rendered equally competent to carry out proper phenotypic gene expression.
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Subsequently, our group provided further evidence of mitotic bookmarking in 2007 and
2008 [98-100]. Lineage-specifying factors MyoD, myogenin, RUNX2, and C/EBPβ
replaced Myc, which occupies and activates rRNA genes during proliferative stage of
multipotent mesenchymal stem cells, during mesenchymal progenitor differentiation and
suppressed RNA Pol I-mediated transcriptional control of rRNA genes through
interaction with UBF-1. Consistently, these lineage-specifying factors also occupied
RNA Pol-II regulated genes involved in cell proliferation and fate determination.
Evidence began to grow for mitotic bookmarking as Kadauke et al.
demonstrated in 2012 that GATA1, a hematopoietic-specific transcription factor required
for erythroid development, occupied target genes during mitosis that were rapidly
reactivated upon completion of cell division [101]. Arampatzi et al demonstrated in 2013
that components of the MHC Class II enhanceosome (MCE), a multi-protein complex
necessary for MHC Class II gene transcription, were dynamically associated with
chromatin during mitosis [102]. Furthermore, a subunit of the MCE, Nuclear
transcription factor Y-A (NFYA), recruits PP2A to a specific DRA gene enhancer region
(LCR/XL4) and causes localized chromatin decompaction for timely reactivation of
transcription following mitosis. Caravaca et al. further supported mitotic gene
bookmarking by examining pioneer transcription factor FoxA1, an important
transcription factor involved in liver development [103]. During mitosis, FoxA1 was
shown to occupy a subset of interphase-specific genes important for liver differentiation.
FoxA1 also exhibited non-specific binding to mitotic chromatin in the “vicinity of other
target genes”. Regardless of specific or non-specific binding, the group concluded that
19

both means of FoxA1 binding facilitate early gene reactivation following exit from
mitosis. Lerner et al. also provided additional evidence for mitotic gene bookmarking a
few years later in 2016 [104]. Hepatocyte nuclear factor 1 β (HNF1β), a transcription

Figure 7. Current established proteins known to mitotically bookmark target genes, as well as the
signaling pathways and chromatin modifying properties associated with mitotic bookmarking.
Figure From Zaidi SK, et al. [7]

factor important for early steps of pancreas, kidney, and liver development, was shown to
occupy mitotic chromatin. The study also examined the roles of clinically relevant
mutations found in HNF1β of patients suffering from renal multicystic dysplasia and
diabetes. These mutations had prevented HNF1β to mitotically bookmark DNA.
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These reports demonstrate mitotic retention of tissue-specific transcription
factors as a key epigenetic mechanism for regulation of genes that coordinately control
cell growth and identity upon exit from mitosis (Fig. 7). Although significant evidence
has accumulated for mitotic gene bookmarking in maintenance of normal tissue-specific
cellular identity, a compelling question is how mitotic gene bookmarking maintains a
cancer-like phenotype.

3.3. Supporting Evidence of Mitotic Gene Bookmarking
Upon entering mitosis, the cell undergoes significant structural and biologicallyrelevant changes. The most generally accepted finding was that RNA transcription in the
nucleus is ceased when a cell enters mitosis [105-107]. This is mostly a result of RNAP II
complexes being displaced from mitotic chromosomes. However, it was also shown that
a small portion of genes maintained these complexes during mitosis [108]. Using a
sensitive approach to detect transcription during mitosis, Zaret and colleagues recently
reported a finding challenging the long-standing paradigm of transcription being halted
during mitosis [109]. These authors pulse-labeled nascent transcripts with 5ethynyluridine, a non-radioactive cell-permeable molecule and demonstrated that
transcription of genes required for vital cellular processes such as cellular growth and
proliferation occurs in waves, mostly in mid to late mitosis. The genes more important in
cellular phenotype and identity were transcribed immediately following mitosis. This
finding provides a strong supportive role for mitotic gene bookmarking, especially for
genes that are involved in vital cellular processes such as growth and proliferation.
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Components of RNAP I transcriptional machinery, mainly upstream binding
transcription factor 1 (UBF1) have been reported by our group (and others) to occupy
ribosomal RNA genes during mitosis [99, 110]. Since protein synthesis by the cell is
directly related to cellular growth and proliferation, mitotic retention of these complexes,
combined with steady state levels of transcription during mitosis, ensures competency of
a cell to maintain its growth potential following cell division. Beyond rDNA
transcription, components of RNAP II transcriptional machinery, such as TATA-binding
protein (TBP), have also been shown to occupy target genes during mitosis and lead to
their immediate reactivation following mitosis through recruitment of RNAP II [111].
RNAP II transcriptional machinery is responsible for transcription of genes involved in
cellular identity and phenotype. The discovery of steady state transcription during mitosis
agrees with the accumulated evidence for mitotic gene bookmarking through tissue
specific transcription factors as well as components of RNAP I and II transcriptional
machinery.
Mitotic chromatin is highly condensed, resulting in displacement of numerous
transcription factors, as many sequence specific binding sites of transcription factors are
hidden or inaccessible. However, if steady state levels of transcription are occurring
during mitosis, then a small portion of mitotic chromatin must remain uncondensed for
regulatory machinery to bind and perform its function. Reports by a few research groups
have addressed accessibility of mitotic chromatin by utilizing state-of-the-art approaches
to analyze the three-dimensional conformation of chromatin in interphase and mitotic
cells [106, 112, 113]. These studies have identified regions of mitotic chromatin in an
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open conformation and therefore, accessible for regulatory proteins to bind. These
euchromatic regions of mitotic chromatin share properties including nuclease
accessibility, enrichment of unique histone variants, and association of cohesion with
actively transcribed genes.
Histone variants and post-translational modifications such as H2A.Z, H3.3, and
H3K4me3 are also shown to be enriched in the nucleosomes of mitotically bookmarked
genes [114, 115]. Histone modifications often associated with activation of genes (i.e.
H3K4me3 and H3K27Ac) have been frequently found at the promoters of mitotically
bookmarked genes [116]. Although further research is necessary, it appears that specific
histone variants and post translational modifications are associated with mitotically
bookmarked genes and provide a suitable chromatin environment to facilitate and/or
enhance mitotic retention of regulatory factors on DNA.

3.4. Mitotic Gene Bookmarking Maintains Cancer Phenotypes
The most fundamental characteristics of tumor phenotypes include uncontrolled
cellular growth with a deregulation of differentiation, both of which lead to an
accumulation of clonally selected cells in a tissue that disrupts homeostasis. Given the
documented examples of mitotic gene bookmarking thus far, it comes as no surprise that
this epigenetic mechanism can have significant roles in maintenance of a cancerous
phenotype. Examples of mitotic gene bookmarking sustaining cancerous phenotype
comes from studies within leukemia. AML1-ETO, an oncogenic fusion protein found in
acute myeloid leukemia (AML) patients, regulates vital cellular processes such as
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differentiation, proliferation, apoptosis, and self-renewal to promote leukemogenesis and
maintain a leukemic phenotype both in vivo and in vitro (reviewed in [117]). AML1-ETO
mitotically bookmarks rRNA genes, genes required for proliferation, as well as genes
involved in myeloid cell differentiation. In comparison to normal AML1/RUNX1, a
phenotypic transcription factor primarily involved in hematopoiesis and myeloid
differentiation, AML1-ETO causes the opposing regulatory effect on mitotically
bookmarked genes. Ribosomal RNA and genes involved with cell proliferation are
upregulated with AML1-ETO occupancy during mitosis, which causes an enhanced
growth and proliferative potential for these cells. In contrast, genes that are important for
proper myeloid differentiation are down regulated, causing an arrest in a blast-like stage
of differentiation. The lack of myeloid differentiation and enhanced proliferative effects
on blast cells that express AML1-ETO promote leukemogenesis and help maintain a
leukemic phenotype [118].
Mixed lineage leukemia protein (MLL) is another example of mitotic gene
bookmarking maintaining a tumor phenotype. MLL is a chromatin remodeling factor that
bookmarks target genes involved in leukemogenesis. Mitotic occupancy of target genes
by MLL recruits chromatin remodeling machinery to these genes and poises them for
rapid reactivation following mitosis, thus maintaining the leukemic phenotype [119].
Furthermore, another fusion protein demonstrated mitotic gene bookmarking activity.
CBF-β, the obligatory binding partner for RUNX proteins, forms a fusion protein with
smooth muscle myosin heavy chain (SMMHC) in inv(16) AMLs [120]. This fusion
protein is required for survival of inv(16) AML cells [121]. Like AML1-ETO, the CBFβ24

SMMHC fusion protein was also capable of mitotically bookmarking rRNA genes, with a
suggested repressive role [122].
The current examples of mitotic gene bookmarking maintaining cancerous
phenotype have thus far been demonstrated in leukemia. Given the variety of
transcription factors involved in numerous processes such as controlling cell growth,
proliferation, and cellular identity/phenotype, it is inevitable that other tumor phenotypes
are maintained either partially or substantially through mitotic gene bookmarking of
specific target genes. Further studies are required to determine if other oncogenic
proteins, similar to AML1-ETO and MLL, mitotically bookmark target genes to maintain
cancerous phenotypes in different tissue-specific contexts.

3.5. Models and Techniques for Investigation of Mitotic Gene Bookmarking
With rapid evolution and development of state-of-the-art approaches to study
gene expression and genome organization, there are now more robust technical
approaches to study mitotic gene bookmarking and investigating its role in different
cellular and tissue specific contexts.
A key approach for investigating localization of target proteins within mitotic
cells is through immunofluorescence microscopy (IF). This well-established technique
can be readily employed to visualize the localization of a protein in a variety of cells
regardless of their stage of the cell cycle. One critical component of this technique is the
requirement of suitable and validated antibodies targeting the protein of interest. Potential
masking of the epitope on the target protein of interest because of normal mitotic-related
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cellular events such as chromatin compaction and post translational modifications are
possible and should be taken into consideration for antibody selection. Typical IF
experiments are performed in fixed cells, which also warrants some considerations.
Different fixation reagents could potentially disrupt antibody binding to its intended
target [123]. Overexpression of a target protein that is linked to a fluorescent molecule
such as GFP allows for live cell imaging and avoids some of these potential issues.
However, overexpression of a protein with a fluorescent tag can introduce different
mitotic occupancy patterns and should be taken into consideration. Proteins that
mitotically bookmark target genes involved in cell growth, proliferation, and phenotype
interact with other proteins or have obligate binding partners whose interactions may be
disrupted with the introduction of a fluorescent-tagged molecule. The fluorescent tag on
the protein of interest may also affect protein folding and, as a result, can lead to
differences in DNA binding affinity (for transcription factors). Various DNA stains allow
for visualization of condensed chromatin during mitosis, as well as for identification of
substages of mitosis based on the topology of DNA staining. Overall, IF is a valuable tool
for providing evidence of a protein in its endogenous form and natural environment being
mitotically retained on DNA during mitosis, thus providing the foundation for further
investigation.
Chromatin immunoprecipitation (ChIP) is another vital technique to
biochemically validate mitotic gene bookmarking. When coupled with high throughput
sequencing (ChIP-Seq), specific genes bound by the protein of interest can be identified.
Antibody requirements for ChIP-Seq are more stringent in comparison to IF. The purity,
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specificity, and concentration of antibodies used in ChIP-Seq are often vital for
successful ChIP-Seq experiments. ChIP-Seq is also dependent upon endogenous levels of
the target protein in the specific cellular model. Lower levels of endogenous protein will
most likely require a larger amount of chromatin, and therefore more antibody for
successful ChIP-Seq [124]. The use of more antibody for ChIP-Seq can lead to potential
non-specific immunoprecipitation. To overcome low endogenous levels of protein or a
low affinity antibody, an overexpression of the target protein labeled with a molecule
which has strong antibodies against it (i.e., FLAG, V5, etc.) can be utilized, but also has
shortcomings. Similar to the overexpression issues described for IF, overexpression and
labeling with a molecule like FLAG can change mitotic occupancy patterns, or even
mitotic occupancy dynamics (in the case of non-specific binding). A more suitable
alternative would be endogenous tagging using precision genome editing. Regardless,
any alterations to the endogenous protein carries the potential of differential mitotic
occupancy patterns. ChIP-Seq must be performed in a population of pure mitotic cells.
Depending on cellular model, cells can typically be arrested with a cell-cycle disrupting
agent such as nocodazole or colcemid. Following optimized conditions for mitotic arrest,
an optimized mitotic shake off procedure should be utilized for harvest of only
mitotically arrested cells. Fluorescently activated cell sorting (FACS) protocols
involving mitotic-specific markers such as H3Ser10p can be used to accurately evaluate
the purity of the mitotic population of cells and also utilized to sort them from nonmitotic cells [125].
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RNA-Seq is a technique used to investigate the expression of genes through
detection of mRNA levels, however it is also capable of detecting miRNAs, siRNAs, and
lncRNAs, all of which are non-coding in nature [126]. Pertaining to mitotic
bookmarking, levels of mRNA can be detected for bookmarked genes at specific stages
of the cell cycle. For example, if cells are synchronized into early G1, RNA-Seq could
determine the expression of bookmarked genes upon immediately exiting mitosis. With
use of a small molecule inhibitor to disrupt mitotic bookmarking, looking at the
expression of bookmarked genes in G1-synchronized cells treated with or without the
inhibitor should theoretically reveal differences in expression of only bookmarked genes.
As beneficial as this can be, it has a critical limitation in that it is only capable of
detecting total RNA levels present within the cells. Detection of nascent RNAs would
truly reflect differences in gene expression. GRO-Seq (Global Run-on Sequencing) is a
technique which detects levels of only nascent RNAs [127, 128].

Briefly, cells

incorporate 5-bromouridine 5’-triphosphate (BrUTP) to tag nascent RNAs. Following
this tagging, controlled time for transcription, and subsequent harvest of RNA, beads
coated with 5-bromo-2’-deoxyuridine (BrdU) are used to isolate the tagged nascent RNA.
This nascent RNA can be sequenced to determine gene expression of only the newly
transcribed genes. When this technique is coupled with a cell synchronization into G1
and coupled with another technique to disrupt mitotic bookmarking (i.e. small molecule
inhibitor disruption, inducible knockout, etc.), a difference in expression of newly
transcribed genes which are also mitotically bookmarked can be determined.
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By taking the necessary considerations into account for IF and ChIP-Seq, these
two techniques validate mitotic retention of factors on target genes during mitosis. Some
results have been published which show discordant results between IF and ChIP-Seq. In
one example, GATA1 was shown to be excluded from DNA during mitosis through IF,
yet ChIP-Seq findings for GATA1 revealed a number of genes occupied during mitosis
[101]. This disagreement between techniques could be explained by chemical fixation
conditions for both protocols. In a recent report, Teves et al. investigated the artifacts of

Figure 8. A proposed hypothesis for chemical artifacts
regarding experimental visualization of transcription factor
retention. Figure from Teves SS et al. 2016 [3]

chemical fixation for evaluating mitotic gene bookmarking (Fig. 8) [3]. Using live cell
imaging, they demonstrated that 2 secs prior to 1% paraformaldehyde treatment, their
target protein (H2B-GFP) was present on mitotic chromatin. After 10 secs following
addition of 1% paraformaldehyde treatment, the levels of H2B-GFP on the chromosomes
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was markedly reduced, and was indistinguishable from cytoplasmic signal by 60 sec.
With this data, they proposed a potential mechanism of formaldehyde fixation, in which
the chemical fixation prevents transcription factors from binding to mitotic chromatin.
Briefly, fixative entering the cell would first cross-link cytoplasmic protein as it makes its
way towards the nucleus. Therefore, the cytoplasmic pool of protein association rate (kon)
would be greatly diminished due to the crosslinking. Taking into account the short
residency times of transcription factors on DNA, mentioned to be under 20 sec based on a
set of recent fluorescent recovery after photobleaching (FRAP) experiments [129, 130],
the protein occupying mitotic chromatin may be evicted as a result of formaldehyde
fixation. This artifact of chemical fixation would be exacerbated in highly dynamic
transcription factors. Other chemicals can be used for fixation including MeOH and
glutaraldehyde, although they carry other potential considerations as they are better suited
for different techniques such as electron microscopy.
A variety of auxiliary approaches can be taken to provide supporting evidence
of a protein occupying target genes during mitosis and interphase. For example, it is
known that specific histone marks indicate either up-regulation of nearby genes
(e.g.H3K4me3, H3K27Ac) or down regulation of nearby genes (e.g. H3K27me3) through
association with euchromatic or heterochromatic states of DNA. By correlating a specific
gene mitotically occupied during mitosis with either an active or repressive histone mark
can help parse out a global picture of mitotic gene bookmarking. DNase hypersensitivity
assays also reveal genes that are accessible by the nuclease, and therefore in a
euchromatic state. Determining the structure of chromatin at gene loci that are mitotically
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bookmarked can provide additional regulatory information critical to discern expression
of these genes following cell division.
Lastly, downstream applications such as reverse transcription- quantitative
polymerase chain reaction (RT-qPCR and western blot should be utilized to examine the
regulation of specific genes mitotically occupied during mitosis. Use of an inhibitor to
disrupt the bookmarking activity yet maintain protein levels is perhaps the most suitable
to determine the immediate effects of disrupted mitotic bookmarking activity. An
alternative approach can be the use of CRISPR gene editing technologies to introduce
mutations into the DNA binding domain of endogenous protein, therefore disrupting
mitotic bookmarking while maintaining protein levels. Techniques such as RNA
interference can also be used to deplete the cellular model of target protein and therefore
mitotic bookmarking, although the characterized differences observed after depletion
may not entirely be attributable specifically to disruption of mitotic gene bookmarking
activity.
Taken together, approaches to evaluate mitotic occupancy of target genes by
various factors require important considerations for valid interpretation of the data.
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CHAPTER 4: AML1/RUNX1
4.1. AML1/RUNX1 Overview and Introduction
Runt-related transcription factor 1 (RUNX1), also referred as acute myeloid
leukemia 1 protein (AML1), is a lineage-specifying transcription factor from the Runx
family of proteins (Fig. 9). The RUNX family of proteins consists of RUNX1/AML1,
Runx2/CBF-alpha-1, and Runx3/PEB2Pα. RUNX proteins are lineage-specifying
transcription factors that share a highly conserved Runt domain (similar to the conserved
domain found in the runt gene of Drosophila), which binds to DNA and mediates for
specific protein-protein interactions [131-133]. RUNX DNA-binding capabilities is
intimately tied with its obligate binding partner, Core binding factor – Beta (CBF-β).
When RUNX proteins interact with CBF-β, specificity and affinity of Runx proteins for
their target genes increases considerably (~6-10 fold) in comparison to RUNX proteins
alone [134-139]. This is the result of a favorable conformational change induced by CBFβ on the DNA binding domain structure to increase binding affinity [140]. RUNX

Figure 9. Runx1’s DNA- and protein-interacting domains with co-binding partners identified. AD:
Activating domain, ID: inhibitory domain. Figure from Ito Y et al, 2015. [4]

proteins are predominantly localized in the nucleus. RUNX proteins contain a nuclear
localization signal on the C-terminal side of the Runt domain which is responsible for
nuclear localization of Runx proteins. In addition, RUNX proteins contain a conserved C32

terminal sub-nuclear matrix-targeting signal, which targets RUNX proteins to punctate
domains [141-145]. The nuclear matrix targeting signal is also responsible for interaction
with other co-regulatory factors. RUNX proteins also interact with co-activators and corepressors through their PY and VWRPY motifs in a tissue-specific manner [146-151] [4,
131, 146-148, 152]. Physiological activities of RUNX proteins are thus dictated by their
interactions with target genes and co-regulators.
RUNX1 is a critical transcription factor required for hematopoietic development
[153, 154]. Hematopoiesis is divided into two main stages: primitive and definitive.
Primitive hematopoiesis is the earlier developmental stage which begins at day 7.5 and is
limited to the extra-embryonic yolk sac. During this stage, three main precursor cell types
arise: erythrocytes, macrophages, and megakaryocytes (reviewed in [155], [156-159]). It
isn’t until definitive hematopoiesis when erythrocyte precursors from primitive
hematopoiesis differentiate and give rise to the hematopoietic stem cells (HSC), which
are multipotent cells capable of differentiating into all hematopoietic sub-lineages
including myeloid and lymphoid cells [158, 160, 161]. RUNX1 deficient mice lack the
hematopoietic stem cell progenitors that normally arise during definitive hematopoiesis, a
phenotype that is mimicked by a CBF-β knockout as well, the obligate binding partner of
Runx1 [153, 162-166]. RUNX1 deficient mice are embryonically lethal around
embryonic day 12.5 due to the absence of definitive hematopoiesis [153, 165, 167].
RUNX1 is also responsible for differentiation of other cell types during normal
hematopoiesis which include megakaryocytes, B-Cells, and T-Cells [168-171].
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Because RUNX1 is expressed in several human tissue types, its function is not
limited to hematopoiesis. RUNX1 has been shown to play regulatory roles in the
development of bone, nervous system, mammary gland, muscle, and even hair follicle
tissues [172-179]. RUNX1 also has an implicated role in embryogenesis [180-182].
Around day 5.5, human embryonic stem cells (hESCs) undergo mesendodermal
differentiation. During this period, a transient spike of RUNX1 expression occurs, and
promotes a controlled, physiological EMT event that is vital for the differentiation of
early mesendodermal cells through TGFβ signaling. RUNX1 transcription from the
proximal P2 promoter is associated with this transient expression during embryonic
development. Transcription of RUNX1 from the P2 promoter is predominantly isoform
1b, whereas expression from the distal P1 promoter yields isoforms important for
hematopoietic development [153, 181, 183, 184]. The P2 promoter also contains bivalent
histone marks (H3K27me3 and H3K4me3) which poises many genes in stem cells for
rapid activation or inactivation, further highlighting RUNX1 role in embryogenesis [185188].
More recently, RUNX1 has been shown to be involved in different stages of
mammary gland development. RUNX1 levels are highest during virgin and earlypregnancy stages of mammary gland development but decrease as the mammary gland
progresses into late-pregnancy and lactation [178, 189, 190]. Basal progenitor cells have
higher RUNX1 levels in comparison to luminal cells. The stages where alveolar luminal
cells arise i.e. late pregnancy and lactation, RUNX1 expression is lost. It is hypothesized
that loss of RUNX1 during this developmental stage of the mammary gland is required
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for milk production and secretion [178]. RUNX1 has also been shown to be vital in
facilitating mammary stem cell differentiation into mature lobules and ducts [176].
Lastly, targeted RUNX1 deletion in mouse mammary glands was shown to decrease the
number of ER+ luminal cells, through repression of Elf5, a transcription factor important
in mammary gland ductal differentiation [178].
Because RUNX1 plays critical roles in physiological development and
differentiation in so many different tissues, it is informative to examine how RUNX1
aberrations/mutations/defects can lead to improper differentiation and development.

4.2. RUNX1 in Hematologic Malignancies
The first translocation identified in a cancer was the t(8;21) (also referred to as
AML1-ETO, RUNX1-ETO, RUNX1-MTG8, RUNX1-RUNX1T1) translocation in acute
myeloid leukemia in 1973 [191-194]. Since then, a significant amount of research has
revealed multiple roles the resulting AML1-ETO fusion protein plays in the onset and
progression of leukemia as well as in maintaining a leukemic phenotype. The fusion
protein consists of the first 5 exons of RUNX1 from chromosome 21 with the ETO gene
from chromosome 8 [195-197]. In the unaltered RUNX1 transcript, the C-terminus
contains both a subnuclear targeting domain for RUNX1 subnuclear localization as well
as a conserved motif that facilitates protein-protein interactions; both these domains are
vital for RUNX1 biological activity [195, 198, 199]. The t(8;21) translocation disrupts
normal RUNX1 activity. Since the DNA binding domain is unaltered, AML1-ETO is
occupies RUNX1 target genes, however their regulation is disrupted [152]. AML1-ETO
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forms co-repressor complexes with NCOR1, HDAC1, and SIN3A/HDAC [200-205].
Furthermore, because ETO replaces RUNX1 subnuclear targeting domain, the AML1ETO fusion protein is localized to different subnuclear domains than the ones where
normal RUNX1 resides [199]. The deregulation of RUNX1 target genes and altered
subnuclear targeting are considered the primary mechanisms by which AML1-ETO
results in the leukemic phenotype.
Another mechanism by which AML1-ETO contributes to leukemic phenotype is
through transcriptional regulation of miR-29b-1 [197]. MicroRNAs (miRs) and their role
in regulating transcription of virtually every biological pathway is a relatively newer field
that is heavily researched. By binding to the 3’ untranslated region (3’ UTR) of
transcripts for certain genes, they can inhibit that mRNA’s translation. It was
demonstrated that AML1-ETO downregulates miR-29b-1, a mIR that also targets AML1ETO for its repression. The study unraveled a unique regulatory circuit miR-29b-1 and
AML1-ETO with their respective downstream targets. AML1-ETO not only directly
binds to the promoter region of mIR-29b-1, it also inhibits C/EBPα, a target gene who
activates mIR-29b-1, thus causing indirect regulation of mIR-29b-1 by AML1-ETO [197,
206]. mIR-29b-1 downstream targets affecting leukemic phenotype are Myc, Akt2, and
CCND2, all of which have roles in regulation of cell growth, DNA Repair, Apoptosis,
and cell cycle [207].
Several other translocations involving RUNX1 have been found in leukemic
patients and/or contribute to leukemic phenotype. These include the t(12;21) and the
t(3;21) translocations, which encode TEL-RUNX1 and EVI-RUNX1 (also called MDS136

RUNX1 or EAP-RUNX1), respectively [208-214]. There are currently 55 translocations
involving RUNX1, of which only 21 are well-studied [215]. Furthermore, a variety of
mutations within the RUNX1 gene have been identified with specific disease states and
cancers (reviewed in [209] and [216]). Mutations in the Runt domain of RUNX1 have
been associated with AML, myelodysplastic syndrome (MDS), myeloproliferative
neoplasms (MPN), and chronic myelomonocytic leukemia (CMML) [217-221].
Haploinsufficiency of RUNX1 has also been associated with Familial Platelet Disorder
with predisposition to AML (FPD/AML) [222]. Additionally, mutations outside of the
Runt domain have been suggested to play roles within the disease state for MDS and
CMML [223-225]. Overall, it has been estimated that a combined estimated frequency of
RUNX1 mutations within AML adult patients is approximately 28% [216].

4.3. RUNX1 in Breast Cancer
Recently, mutations within CBFβ and RUNX1 were identified as novel recurrent
mutations found within breast cancer [226]. The mutations in CBFβ were comprised of
both truncating mutations as well as missense mutations, both of which disrupt
interaction with RUNX1. The alterations in RUNX1 were primarily deletions, also
resulting in the disruption of CBFβ-RUNX1 interaction. This study was the first to
associate CBFβ and RUNX1 complex inactivation within an epithelial cancer [226-228].
In another study, CBFβ and RUNX1 were identified as novel significantly mutated genes,
with CBFβ harboring 9 mutations and RUNX1 harboring 19 mutations [168]. The authors
suggested that these mutations in CBFβ and RUNX1 play an important role in ERα
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signaling, a pathway that is heavily involved in mammary gland development and
intersects with RUNX1, i.e. RUNX1 tethers ERα to novel DNA binding sites [229, 230].
Mutations in CBFβ and RUNX1 were identified in luminal A, luminal B, and Her2enriched cancer subtypes, but not basal-like [168]. Using cBioPortal, a database of gene
alterations in cancer patients, 3002 sequenced breast cancers across 3 separate studies
were examined for RUNX1 mutations [231-236]. RUNX1 exhibited a somatic mutation
frequency of 4.1% with a total of 132 mutations. 87 of these mutations were truncating
and found throughout RUNX1, including the Runt domain. 33 mutations were found to be
missense mutations residing across RUNX1. 5 mutations were described as in-frame and
7 were described as “other.” Evidence supports that both mutations disrupting CBFβ and
RUNX1 interaction as well as those in the Runt domain of RUNX1, have important roles
in tumorigenesis of breast cancers. Consistent with these findings, RUNX1 is not
expressed or expressed at very low levels in differentiated/metastatic breast tumor
samples compared to normal breast tissue. Importantly, RUNX1 also suppressed tumor
growth [237]. Despite the preliminary observations regarding RUNX1 suppressing breast
tumor growth, the underlying mechanisms have not yet been established.
More recent studies indicate two opposing roles of RUNX1 in breast cancer.
Reduced RUNX1 expression correlated with Fork head box O (FOXO1) upregulation,
leading to the hypothesis that RUNX1 results in subsequent tumor progression [238].
Normal mammary epithelial cells with RUNX1 loss led to increased proliferation and
altered cellular morphology within a 3D Matrigel assay which was dependent upon
normal FOXO1, indicating that RUNX1 and FOXO1 coupled together inhibit tumor
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progression [239, 240]. A separate study examining RUNX1 loss in mammary epithelial
cells demonstrated a reduction in ER+ luminal cells, indicating that RUNX1 is a positive
regulator of the ER+ luminal lineage [178]. Additionally, this study demonstrated that
these ER+ luminal cells lost by RUNX1 depletion, could be rescued by loss of either
TP53 (p53) or RB1 (Retinoblastoma protein). RUNX1 was also shown to control
estrogen-mediated AXIN1 transcriptional repression in ER+ breast cancer cells [241]. By
deregulation of β-catenin, a critical protein in Wnt signaling, driven by loss of RUNX1,
ER+ RUNX1-deficient breast cancer cells were associated with compromised mitotic
checkpoint control, increased cell proliferation, as well as a more mesenchymal
phenotype by increased expression of stem cell markers [241].
Although there are two separate proposed roles of RUNX1 in breast cancer
onset/progression, RUNX1 as a tumor suppressor has become the more well established
and understood role.

4.4. RUNX Proteins and Mitotic Gene Bookmarking
The first reported instance of mitotic bookmarking described the mitotic
occupancy of genes by RUNX2 in Saos-2 cells [97]. RUNX2 was demonstrated to be
stable during mitosis and occupy sequence-specific sites on mitotic chromatin. Through
use of siRNA-mediated knockdown of RUNX2 and ChIP-Seq, genes involved in cell
growth and differentiation were identified to be regulated post-mitotically by RUNX2.
This finding strongly supported the role of mitotic gene bookmarking in maintaining
cellular phenotype. Further defining the role of RUNX2 bookmarking within Saos-2
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cells, our group discovered RUNX2 mitotically bookmarking both RNA Pol I and II
transcribed genes for coordinated control of cellular growth, proliferation, and phenotype
[99, 100]. RUNX2 is associated with rDNA and controls rRNA expression, which
ultimately leads to differences in global protein synthesis. By mitotically bookmarking
both RNA Pol I and II transcribed genes, the strong foundational hypothesis of
coordinated cellular control by phenotypic transcription factors such as RUNX2 was
established. This makes conceptual sense, as a cell cannot entirely shift its overall
phenotype, for example from epithelial to mesenchymal, without changing multiple
attributes. A cell’s phenotype will not change by dysregulation of phenotypic-related
genes that dictate morphology, size, structure, polarity, etc. without an accompanying
dysregulation in genes that dictate cellular growth and proliferation, and vice versa. It
makes conceptual sense that transcription factors capable of this coordinated regulation
of RNA Pol I and II transcribed genes would be mitotically bookmarked, therefore a
parental phenotype is maintained throughout successive cell divisions, primarily by a few
vital phenotypic transcription factors. This coordinated control of cellular phenotype by
other transcription factors in different cellular lineages [98]. Transcription factors such as
MyoD and CEBPα were also capable of mitotically bookmarking and regulating rRNA
expression, on top of their already established roles in regulating RNA Pol II-transcribed
genes [242-244]. These findings from our group established mitotic gene bookmarking as
a novel epigenetic mechanism for coordinately controlling cellular phenotype.
RUNX1, which shares the conserved Runt (DNA binding) domain with RUNX2
and RUNX3, was investigated for mitotic bookmarking capabilities. Given RUNX1’s
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role within proper hematopoiesis, mitotic bookmarking was investigated within Jurkat (a
T-lymphocyte lineage which expresses high levels of RUNX1/AML1) and Kasumi-1
cells (a leukemic cell line which possesses the AML1-ETO t(8;21) translocation) [118].
The AML1-ETO translocation is present in a significant portion of patients (~15%) who
suffer from AML [245]. This translocation retains AML1/RUNX1’s Runt domain,
however the nuclear localization signal and transactivation domain are lost [145, 199]. It
was determined that both RUNX1/AML1 and AML1-ETO were capable of mitotically
bookmarking rRNA genes, however, they exhibited different regulation. RUNX1/AML1
was shown to repress rRNA genes whereas AML1-ETO was shown to activate rRNA,
most likely contributing (in part) to the leukemic phenotype [118].
Taken together, these findings by members of our group demonstrate RUNX
proteins capable of mitotically bookmarking genes in both normal and cancer cells which
contribute to maintenance of cellular phenotype through both RNA Pol I and II regulated
genes. RUNX proteins are phenotypic transcription factors capable of coordinately
controlling these large cellular attributes such as cellular growth, proliferation, and
phenotype specifically through the epigenetic mechanism of mitotic gene bookmarking.
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CHAPTER 5: RATIONALE FOR INVESTIGATION AND CENTRAL
HYPOTHESIS
RUNX1 has established roles in physiological tissue development, especially in
the mammary gland. Importantly, significant somatic mutations in RUNX1 have been
discovered in breast tumors, indicating that RUNX1 plays a consequential role in breast
cancer formation/progression. Recently, our group showed that RUNX1 functions as a
tumor suppressor in a normal breast epithelial cells [9]. RUNX1 maintains epithelial
phenotype and prevents EMT through transcriptional regulation of genes involved in key
cellular pathways including TGFβ pathway.
This dissertation tests the hypothesis that RUNX1 is persistently retained on
chromatin throughout the cell cycle (including mitosis) at RNA Pol I- and IItranscribed genes in breast epithelial cells to maintain epithelial cell phenotype.
Perturbation of RUNX1 mitotic bookmarking leads to EMT, an essential driver of
breast cancer formation and progression.
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RESULTS
RUNX1 associates with mitotic chromatin and occupies target genes
To investigate RUNX1 protein localization and expression within mitotic
MCF10A breast epithelial cells, a protocol for isolating three distinct cell cycle-specific
populations of cells was conducted (Fig. 10). MCF10A cells were treated with either
DMSO as a negative control or 50ng/mL Nocodazole for 16 hr to arrest cells in mitosis
(Fig. 10A). Cells were synchronized into G1 with a media replacement following mitotic
arrest (Fig. 10A). Mitotic shake off was used to harvest mitotic populations of cells.
Fluorescently activated cell sorting (FACS) analysis was conducted to determine purity
of each harvested population using PI/RNase stain for DNA content, shown by a
representative FACS Profile (Fig. 10B). Expression of cell-cycle specific proteins were
examined to further validate the purity of each harvested population of MCF10A cells

Figure 10. Validated experimental approach for analysis of RUNX1 protein within MCF10A breast
epithelial cells. A) Protocol for harvest of three MCF10A cell populations: DMSO = Asynch (A), Mitotic
= Blocked (B)(M), G1 = Released (R)(G1). B) Fluorescently activated cell sorting (FACS) analysis of
PI/RNase stained MCF10A treatment groups. C) Western blot of MCF10A treatment groups for cell cyclespecific proteins Cyclin B1 (top), CDT1 (middle), and Lamin B (bottom).
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(Fig. 10C).
After validating the purity of harvested MCF10A cell populations, we next
examined RUNX1 levels within each population to ensure RUNX1 was expressed at
detectable levels (Fig 11). Western blot analysis of each cell population revealed
detectable levels of RUNX1, indicating RUNX1 expression within each harvested group
(Fig 12).

Figure 11. Western blot of Asynch (A), Mitotic (M), and G1 MCF10A cell
populations for RUNX1 (top) and Tubulin (bottom).

Given detectable expression of RUNX1 in each harvested population of MCF10A
cells, RUNX1 protein localization and expression was evaluated within actively
proliferating MCF10A cells using immunofluorescence microscopy. Limit of detection
for RUNX1 within MCF10A cells was conducted to observe the minimum amount of
antibody required to observe RUNX1 foci via immunofluorescent microscopy. This was
performed using two separate antibodies against RUNX1 (Fig. 12). In an antibody
validated for use in Western blot and immunofluorescent applications, the most abundant
signal was observed at a 1:10 dilution (Fig. 12A). A chromatin immunoprecipitation
(ChIP) grade antibody was also used, with a RUNX1 signal observed down to 1:600 (Fig.
12B).
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Figure 12. Limit of detection for RUNX1 within actively proliferating MCF10A cells. Blue = DAPI,
Green = RUNX1. RUNX1 foci are indicated by white arrows. A) An antibody validated for use in western
blot and Immunofluorescence (CST 4334S) was diluted to 1:200 (top), 1:50 (middle), and 1:10 (bottom).
B) A ChIP-grade antibody (CST 4334BF) was diluted to 1:200 (top), 1:600 (middle), and 1:1000 (bottom).

Within limit of detection studies, it was clear that RUNX1 signal was comprised
of two major forms: major and minor foci. These foci appeared to remain during mitosis.
To better determine RUNX1 chromatin occupancy within specific substages of mitosis
(prophase, prometaphase, metaphase, anaphase, and telophase) we performed
immunofluorescence microscopy in actively proliferating MCF10A cells (Fig. 13). We
find that RUNX1 is distributed in punctate subnuclear domains throughout interphase
nuclei in MCF10A cells (Fig. 13). Interestingly, RUNX1 is localized on mitotic
chromatin at all topologically identified substages of mitosis (Fig 13). Presence of two
distinct type of foci were validated on mitotic chromosomes: large punctate foci as well
as numerous smaller foci were detected. In agreement with our previous findings,
RUNX1 foci are equally distributed into resulting progeny cells [97]. Presence of
RUNX1 in all stages of mitosis indicates that the protein is stable during mitosis and
appears to associate with chromatin.
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Figure 13. RUNX1 is present in each topologically identified substage of
mitosis in the form of major and minor foci. Blue = DAPI, Green = RUNX1.

From IF experiments it was evident that RUNX1 was associated with chromatin
throughout mitosis, therefore we next addressed if RUNX1 was bound to specific genes
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related to cell identity or cancer progression during mitosis by conducting ChIP-Seq.
MCF10A cells were synchronized in mitosis by Nocodazole treatment (50ng/mL) for
16hr and isolated by nocodazole treatment followed by release of block by media
replacement for 3hr post-block (Fig. 11A). After nuclei isolation, chromatin was
sonicated and gel electrophoresis of DNA from each treatment group (Asynch, Mitotic,
and G1) reveal an appropriately sized range of fragments (200-500bp) suitable for ChIP
using a validated antibody (Fig. 14).

Figure 14. Gel electrophoresis of sonicated lysates (n=2 biological replicates) for ChIP. R = replicate.
A) Sonicated lysates from DMSO (Asynch) harvested MCF10A cells. B) Sonicated lysates from Mitotic
and G1 harvested MCF10A cells.

Following ChIP reactions, the resulting pooled libraries were evaluated by
bioanalyzer to determine quality of libraries prior to sequencing (Fig. 15). Bioanalyzer
traces revealed that ChIP reactions and library construction had been successful and were
of ideal size (maxima of 350-450bp) for reliable and accurate sequencing (Fig 15).
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Figure 15. Bioanalyzer traces of pooled and size selected libraries reveal proper fragmentation range
for accurate sequencing. A) Pooled input libraries. B) Pooled RUNX1-ChIP libraries.

Following high throughput sequencing, the resulting datasets were mapped to the
latest human genome build (hg38) using Bowtie2 [246]. Enriched regions were
determined using Model-Based Analysis of ChIP-Seq [247] and were analyzed at p<10-5
significance level and with an irreproducible discovery rate (IDR) of 0.05. Peak calling
revealed 2,020 genes that include both protein coding (1,426) genes and long non-coding
RNAs (lncRNAs) (594) were bound by RUNX1 in Asynch (Fig. 16B). MCF10A cells
enriched in G1 showed a total of 1,095 genes with 762 protein coding genes and 333
lncRNAs bound by RUNX1 (Fig. 16B). RUNX1 occupied 551 genes (413 protein coding
and 138 lncRNAs) in mitotically enriched MCF10A cells (Fig. 16B). Clustering of
Asynch, Mitotic, and G1 MCF10A cells were generated by seqsetvis (Bioconductor)
(Fig.16A). A comparison of the three cell populations reveal subsets of genes that were
either shared (354 genes) across the three groups or were specific for each, indicating
dynamic binding of RUNX1 during the cell cycle (Fig. 16B). These findings reveal that
RUNX1 bookmarks several hundred target genes during mitosis. A complete list of
RUNX1 bookmarked genes can be found in supplemental material (S. Table 1).

47

Figure 16. RUNX1 occupies protein coding genes and long non-coding RNAs across asynchronous,
mitotic, and G1 populations of MCF10A breast epithelial cells. A) Heatmaps showing peaks called
between A, M, and G1 MCF10A cells (left, middle, and right respectively). B) Venn diagrams illustrating
the number lncRNAs (left diagram) and protein coding genes (right diagram) identified within and between
A, M, and G1 MCF10A populations. C) Gene Set Enrichment Analysis results from interrogating
mitotically bookmarked genes (i.e. genes called within blocked population within 5kb of TSS in MCF10A
populations) against Hallmark Gene sets from Molecular Signatures Database (MSigDB). The top 10 most
significantly overlapping gene sets are shown from top to bottom.

Gene set enrichment (GSE) analysis was performed using RUNX1 bookmarked
genes to identify regulatory pathways (Fig. 16C). Consistent with established roles of
RUNX1 for cell cycle and DNA damage/repair regulation [248-252], pathways involved
with regulation of G2M Checkpoint, p53, and DNA repair, were among the top 10 which
had significant overlap with the mitotically bookmarked genes identified from ChIP-Seq
(Fig. 16C). Relevant to normal mammary epithelial phenotype, both early and late
Estrogen response signaling gene sets had significant overlap with RUNX1 mitotically
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bookmarked genes. Together these findings reveal that RUNX1 bookmarks genes
involved in cell proliferation, growth, and phenotype in normal mammary epithelial cells.
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RUNX1 mitotically bookmarks RNA Pol I-transcribed genes involved in cell
growth
Our ChIP-Seq results revealed that RUNX1 occupies rDNA repeats in MCF10A
cells; all three MCF10A cell populations showed enrichment within the promoter region
of hrDNA (Fig. 17), suggesting a potential regulatory role for RUNX1 regulation of
rRNA in MCF10A cells.

Figure 17. ChIP-Seq tracks for each population of MCF10A
cells at human ribosomal DNA regions. FE = Fold Enrichment.

We confirmed this finding in actively proliferating MCF10A cells by
immunofluorescence microscopy using antibodies specific against RUNX1 and upstream
binding transcription factor (UBF), a transcriptional activator that remains bound to
rRNA genes during mitosis. We find that large RUNX1 foci colocalize with UBF
throughout each stage of mitosis (Fig. 18). Colocalization between RUNX1 and UBF was
validated by confocal microscopy. Line profiles of MCF10A cells show that although
RUNX1 and UBF occupy distinct nuclear microenvironments in interphase (n=15), both
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proteins significantly colocalize in metaphase (n=15) (Fig. 19). Taken together, these
findings establish RUNX1 binding to ribosomal DNA repeat regions, visualized through
ChIP-Seq and validated through confocal microscopy, for the potential role in regulating
rRNA expression in MCF10A breast epithelial cells. We experimentally addressed the
hypothesis that RUNX1 regulates ribosomal gene expression by using a pharmacological
inhibitor of RUNX1. This small molecule inhibitor binds allosterically to RUNX1’s

Figure 18. RUNX1 colocalizes with upstream binding transcription factor
(UBF) during mitosis. Blue = DAPI, Green = RUNX1, Red = UBF.

obligate binding partner, CBF-β to disrupt the RUNX1-CBF-β interaction [253]. Actively
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proliferating MCF10A cells were treated with a RUNX1 specific inhibitor (AI-14-91) for
6hr, 12hr, 24hr, and 48hr at 20μM; an inactive inhibitor (AI-4-88) was used as a control
under identical conditions. Pre-rRNA expression was significantly increased at 12hr and
48hr timepoints when asynchronous MCF10As were treated with AI-14-91 in
comparison to AI-4-88, indicating that RUNX1 suppresses rRNA genes in normal
mammary epithelial cells (Fig. 20). Because rRNA expression directly correlates with
global protein synthesis, a fluorescent-based detection method was used to determine
newly synthesized proteins in asynchronous MCF10A cells treated with either AI-4-88 or
AI-14-91 for both 24hr and 48hr. MCF10A cells treated with AI-14-91 at 20μM for 24hr
and 48hr appear to have overall decreased levels of global protein synthesis and altered
cell morphology in comparison to AI-4-88 treated MFC10As under identical conditions
(Fig. 21). These findings are further supported by a key observation from our GSE
analysis – that mitotically bookmarked RUNX1 target genes are enriched in mTOR
signaling, a pathway that is required for cell growth and is a therapeutic target in breast
cancers [254, 255]. Together, our results demonstrate that RUNX1 bookmarks RNA Pol I

Figure 19. Confocal immunofluorescence microscopy line profiles validating RUNX1 and UBF
colocalization within MCF10A breast epithelial cells. A) Line profiles representative for N=15
interphase cells. B) Line profiles representative for N=15 metaphase cells.
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regulated rRNA genes during mitosis, transcriptionally represses them and impacts global
protein synthesis in normal mammary epithelial cells.

Figure 20. RUNX1 regulates pre-rRNA expression. Expression
levels were made relative to Beta-Actin. AI-4-88 = Inactive
inhibitor, AI-14-91 = Active inhibitor.
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Figure 21. RUNX1 regulates global protein synthesis within MCF10A breast epithelial cells. Left =
phase contrast, middle/green = DNA (Sytox Green), right/red = nascent proteins. “Protein Label” indicates
the well designation in which cells would be incubated with the protein label as opposed to cycloheximide
or no label for proteins. A) MCF10A cells that have been treated with either inhibitor for 24hr. B)
MCF10A cells that have been treated with either inhibitor for 48hr.
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RUNX1 mitotically bookmarks RNA Pol II-transcribed genes involved in
hormone responsiveness and cell phenotype
Genes involved in both early and late response to estrogen were among the top
identified regulatory pathways from our GSE analyses (Fig. 16C). Estrogen plays vital
roles in normal mammary gland development that include promoting proliferative
phenotypes of mammary epithelial cells for ductal expansion and invasion into breast
tissue [58-60]. We interrogated RUNX1 bookmarked genes with publicly available
Estrogen Receptor Alpha (ERα) ChIP-Seq data sets to identify genes bound by both

Figure 22. Scatterplot of ER-bound genes either up or down regulated in
response to estrogen with RUNX1 bookmarked genes identified.
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RUNX1 and ERα as well as sensitive to estradiol treatment (Fig. 22) [230]. Our analysis
revealed that a subset of mitotically bookmarked by RUNX1 is also bound by ERα, and
either up or down regulated in response to Estradiol, indicating that RUNX1 bookmarks
hormone-responsive genes to regulate proliferation of mammary epithelial cells (Fig. 22).
A list of these genes can be found in the supplemental material (S. Table 2).
Interestingly, GSEA of RUNX1 bookmarked genes revealed regulatory pathways
involved in cellular proliferation and phenotype including TNFα via NFκB, Apical
Junction, E2F targets, and Notch signaling (Fig 16C). Interestingly, NEAT1 and NEAT2
(MALAT1), lncRNAs, often deregulated in cancers [256, 257], were also mitotically
bookmarked by RUNX1. Of the 413 RUNX1 bookmarked protein coding genes, TOP2A,
MYC, HES1, RRAS, H2AFX, and CCND3 are RNA Pol II transcribed genes involved
with proliferation and/or phenotype maintenance (See S. Table 1 for complete list). HES1
and H2AFX show significant fold enrichment between the three populations of MCF10A

Figure 23. ChIP-Seq tracks RUNX1 bookmarked RNA Pol II transcribed genes important for
epithelial phenotype maintenance. A) H2AFX gene ChIP-Seq tracks. B) HES1 gene ChIP-Seq tracks.
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cells (Fig. 23). Recently, HES1 and H2AFX have been identified as regulators of breast
epithelial phenotype [258-260].
Expression of HES1 nearly doubled (relative to Beta Actin expression) upon
inhibition of RUNX1 DNA binding at 48hr, while only increasing slightly (24.7%
relative to Beta Actin expression) at 6hr (Fig. 5C), indicating that RUNX1 acts to repress
HES1. In contrast, the H2AFX expression at 24hr and 48hr was decreased (36% and 26%
respectively, relative to Beta Actin expression), suggesting RUNX1 activates H2AFX
expression (Fig. 24). These results indicate that RUNX1 stabilizes the epithelial
phenotype by bookmarking both protein coding and non-coding genes.

Figure 24. RUNX1 regulates H2AFX and HES1 expression in MCF10A breast epithelial cells. A)
Expression of H2AFX in the presence of RUNX1 inhibitors from 6hr, 12hr, 24hr, and 48hr. B) Expression
of HES1 in the presence of RUNX1 inhibitors from 6hr, 12hr, 24hr, and 48hr.
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We experimentally addressed whether disruption of RUNX1 bookmarking leads
to a change in epithelial phenotype (Fig. 25). After 48hr of treatment with 20μM AI-1491, we find MCF10A cells have adopted mesenchymal-like cellular morphology in
comparison to the identical treatment with AI-4-88, visible by phase contrast microscopy
(Fig. 25A). AI-14-91 treated MCF10As retain RUNX1 foci that colocalize with UBF,
however intensity of RUNX1 signal throughout mitotic chromatin decreased, suggesting
an inability of RUNX1 to bind DNA as a result of pharmacologic inhibition.

Figure 25. RUNX1 inhibition leads to morphological changes in MCF10As visible through
both phase contrast and immunofluorescence microscopy within 48hrs. A) RUNX1 inhibitor
AI-4-88 (Inactive, Top row) in MCF10A cells at 0hr, 24hr, and 48hr. RUNX1 inhibitor AI-14-91
(Active, Bottom row) in MCF10A cells at 0hr, 24hr, and 48hr. B) Immunofluorescence microscopy
of prometaphase MCF10A cells treated with either inhibitor for 48hr. Blue = DAPI, Green =
RUNX1, Red = UBF, Purple = F-Actin.
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Immunofluorescence microscopy also reveals MCF10A cells treated with AI-14-91 for
48hrs have differences in F-Actin protein expression and localization within the cell in
comparison to AI-4-88 treated MCF10A cells, suggesting RUNX1 inhibition leads to
rearrangement of cytoskeletal proteins, an important feature dictating cellular phenotype
(Fig. 25B). Longer term treatment (5 days) of actively proliferating MCF10A cells with
AI-14-91 showed significant cell rounding and loss of adherence, possibly indicating
apoptosis, with a small sub-population of cells remaining attached and adhered with a
transformed, mesenchymal-like phenotype (Fig. 26). After 5 days of treatment, inhibitor
was removed and cells were maintained in normal media after Day 5 of treatment. By day

Figure 26. RUNX1 inhibition causes changes in cellular morphology of MCF10A breast epithelial
cells to a more mesenchymal-like phenotype. (Top row, from left to right) = 0hr, 24hr, and 48hr
timepoints. (Bottom row, from left to right) = 72hr, 96hr, and 120hr.

3-4 following media replacement, cells clearly maintained a mesenchymal-like phenotype
and by day 7 a morphologically heterogeneous population, indicating that MCF10A cells
lacking RUNX1 mitotic bookmarking do not sustain normal mammary epithelial
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phenotype, which mimics the initiating events of tumor formation. These results
demonstrate that RUNX1 is involved in maintaining epithelial morphology and cell
growth, proliferation and phenotypic gene expression, through direct-DNA binding/gene
regulation through the cell cycle, including mitosis. Disruption of RUNX1 gene
bookmarking in normal mammary epithelial cells initiates epithelial to mesenchymal
transition,
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Figure 27. RUNX1 mitotically bookmarks RNA Pol I and II-transcribed genes for maintenance of
normal mammary epithelial phenotype.
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DISCUSSION
RUNX1 associates with mitotic chromatin at RNA Pol I and II-transcribed genes
This study establishes RUNX1 mitotic bookmarking as an epigenetic
mechanism for coordinate regulation of both RNA Pol I- and II-transcribed genes critical
for

mammary

epithelial

proliferation,

growth,

and

phenotype

maintenance.

Pharmacological inhibition of RUNX1 DNA-binding in MCF10A cells causes a
transformation to a mesenchymal-like phenotype, indicating RUNX1 DNA-binding is
required for normal epithelial maintenance.
Consistent with published reports in other cell types [172-179], MCF10A breast
epithelial cells contain RUNX1 signal throughout the interphase nucleus and cytoplasm,
with a slightly increased localization to the periphery of nucleoli, the sites of ribosomal
RNA biogenesis. . Importantly, RUNX1 localizes to major (bright, punctate) and minor
foci on mitotic chromatin in all topologically distinct substages of mitosis. ChIP-Seq of
A, M, and G1 populations revealed mitotically bookmarked RNA Pol I- and IItranscribed

genes

that

regulate

cell

growth,

proliferation,

and

phenotype.

Pharmacological inhibition of RUNX1 in asynchronous MCF10A cells followed by
qPCR of target genes revealed both up- and downregulation depending on the specific
gene, indicating a regulatory role of RUNX1 in controlling the expression of these genes.
Recent reports suggest that RUNX1 is a tumor suppressor in breast cancer [9,
241]. Consistent with these results, RUNX1 often acquires loss of function mutations
within BrCa [168, 226, 261]. We have also shown that loss of RUNX1 is coupled with
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activation of TGFβ signaling pathway, although the precise mechanism for maintenance
of epithelial phenotype by RUNX1 remained unclear. Here, we have defined for the first
time that loss of RUNX1-DNA interaction, specifically through disruption of RUNX1CBF-β interaction, results in a distinct morphological change that may be a precursor to
longer term transformation in breast cancer-related cells. This association of RUNX1
with chromatin throughout the cell cycle suggests that RUNX1-DNA binding activity is
necessary through mitosis to establish proper phenotype upon cell division.

Refined Role of RUNX1 in mammary gland development
Estrogen receptor plays a vital role in directing mammary gland development.
Estrogen is recognized by estrogen receptor alpha (ERα) on breast epithelial cells during
development to help direct a regulated expansion and ductal invasion into the breast
tissue to form the mammary gland [58-60]. Uncontrolled differentiation and proliferation
through ERα signaling contributes to breast cancer phenotype, where about 60% of total
diagnosed breast cancers are “ER+” (subtype classification as luminal A) and respond to
estrogen receptor activity [15]. Therefore, ERα binding sites are among the most
important to understand breast cancer progression.
RUNX1 has been shown to interact with ERα, potentially forming a co-regulatory
complex, at both enhancer regions and transcriptional start sites (TSSs) to modify the
expression of ER-responsive specific genes [230, 241]. Our ChIP-Seq results coupled
with publicly available data sets revealed RUNX1 bookmarking of ERα-occupied,
hormone-responsive genes, indicating that a subset of RUNX1 bookmarked genes is
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regulated by ERα signaling and may be critical for maintenance of breast epithelial
phenotype.
RUNX1 was discovered to play an important role in directing ERα to a subset of
genes which lack an estrogen response element (ERE) [230]. The classical mode of ERα
binding to target genes involves the recognition of an ERE or half-ERE sites. The nonclassical mode of ERα binding involves a protein-protein interaction, described as
“tethering”, where ERα binds to new loci through interaction with another transcription
factor. Evidence supports the physiological significance of this ERα tethering, as
selective estrogen receptor modulators (SERMs), such as tamoxifen, regulate ERα
through agonist binding and therefore disrupt any potential tethering interactions [262].
These ERE-independent genes are also differentially expressed within breast tumors and
respond differently to SERM treatment. [263]. Motif analysis of the ERE-independent,
ERα bound genes revealed RUNX1 as one of the top motifs, thus indicating its role in
tethering ERα to these genes. Interestingly, comparing our RUNX1 mitotically
bookmarked genes in MCF10A cells with the genes bound by ERα and identified to be
either upregulated or downregulated in response to estrogen, there are overlapping genes
(Fig. 5D). GSEA of our RUNX1 mitotically bookmarked genes further supports this role
as two of the top 10 hallmark gene sets (the first and fourth most significant) are involved
in estrogen response (Fig. 2C). These findings suggest that RUNX1 mitotically
bookmarks genes that are occupied by ERα, are sensitive to estrogen treatment and may
be vital in proper breast epithelial cell growth and phenotype.
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RUNX1 regulation of MYC
Our data revealed that RUNX1 binds to an enhancer region of MYC about 67kb
upstream of the transcriptional start site (TSS), as well as about 2500bp downstream of
the TSS (data not shown). This enhancer region was shown to be critical for MYC
activation through ERα and AP-1 mediated transactivation [264]. Furthermore, the MYC
enhancer region contains multiple ERE-half sites as well as two AP1 sites, with only 1
ERE half-site and 1 AP-1 site being critical for this transactivation to occur. AP-1 was the
other motif identified to be important in tethering ERα to target genes [230]. Although
the role for RUNX1 in to the context of ERα transactivation of MYC is not understood, it
most likely has a role based on our ChIP-Seq findings. c-Myc is recognized as a key
protein in promoting cell growth through control of RNA Pol I, II and III mechanisms
responsible for rRNA biogenesis [265]. In addition to RUNX1 directly binding to rDNA
promoters and repressing global protein synthesis, our finding that RUNX1 binds to this
Myc enhancer suggest that RUNX1 also indirectly regulates rRNA biogenesis through
regulating MYC expression. Both MYC and RUNX DNA binding motifs are present in
rDNA repeats [99, 266, 267]. RUNX1 and RUNX2 have been previously shown to
repress rDNA expression and affect global protein synthesis in different cellular models
other than breast epithelium [98-100, 118]. Therefore, RUNX1 likely plays a vital role in
regulating protein synthesis to control cellular growth for mammary epithelial cells
through direct and indirect means.

65

RUNX1 regulation of HES1
Using GSEA to identify and prioritize RUNX1 mitotically bookmarked genes,
one candidate gene of interest is hairy and enhancer of split-1 (HES1). Hes1 is a
transcription factor which represses genes involved in cellular development, and is
primarily regulated by NOTCH signaling, one of our top ten overlapping hallmark gene
sets [268, 269]. HES1 was recently shown to have a role in initiating EMT within
mammary cells [259]. Upon 17β-estradiol treatment of MCF7 cells, Hes1 protein levels
decrease and a proliferative phenotype is observed. However, overexpression of HES1 in
T47D cells was capable of overcoming this 17β-estradiol specific proliferative effect
[259]. Over expression of HES1 was capable of mediating estrogen’s proliferative effect
in MCF7 cells by preventing upregulation of proliferating cell nuclear antigen (PCNA)
[259].
However, the role of HES1 in breast epithelial cells is of current debate. Hes1 is
known to interact with transducin like enhancer of split 1 (TLE1) via conserved WRPW
motifs and recruit histone deacetylases (HDACs) to target genes for repression [270-272].
Products from NOTCH signaling within bone marrow, including HES1, have been shown
to inhibit RUNX2, an osteogenic transcription factor, to maintain a pool a mesenchymal
progenitor cells [273]. It was suggested that this model poises bone marrow to either
activate NOTCH signaling for increased mesenchymal progenitors, or repress NOTCH
signaling for increased bone differentiation. RUNX3 was shown to regulate NOTCH1
signaling through interaction with other co-regulatory proteins at the HES1 promoter,
thus repressing HES1 [274]. This repression was achieved with co-repressing proteins,
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including TLE1, that interact with RUNX3. RUNX1 also contains the conserved
VWRPY motif that mediates interaction with TLE1 for HDAC recruitment and
repression of target genes [147, 275]. Our results indicated that inhibition of RUNX1 led
to an increase in HES1 levels, suggesting RUNX1 acts in part to repress HES1 expression
in MCF10A cells similar to RUNX3 activity in hepatocellular carcinoma cells [274].
More recently, HES1 was shown to have a prominent role in proliferation and invasion of
MCF7 cells [258]. Silenced HES1 led to a downregulation of p-Akt signaling in MDAMB-231 breast cancer cells and ultimately prevented EMT. This finding is also in
agreement with our hypothesis that RUNX1 mitotically bookmarks HES1 for repression
in MCF10A breast epithelial cells.

RUNX1 regulation of H2AFX
Another important RNA Pol II-transcribed gene mitotically bookmarked by
RUNX1 and critical for maintaining mammary epithelial phenotype is histone variant
H2AX (H2AFX). Silencing H2AFX in colon cancer cells led to induction of EMT through
activation of SNAIL2/SLUG and ZEB1 [276]. This regulation was also reported in
MCF10A breast epithelial cells, with the key difference that TWIST1 was activated
instead of ZEB1 [260]. It is shown that SNAIL2/SLUG activation is minor in comparison
to TWIST1 activation in breast epithelial cells, however TWIST1 is activated in both
breast epithelial cells and colon cancer cells upon H2AFX silencing. Potentially, the lack
of TWIST1 expression in breast epithelial cells from our experiments could be due to the
less transformed phenotype of MCF10A cells in comparison to the more
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aggressive/malignant phenotype of HCT116 and HCT15 cells, resulting in differences in
EMT transcription factor expression, although this requires further investigation. Our
RUNX1 inhibition data suggest that RUNX1 activates H2AFX, as H2AFX expression
decreases at 24hr and 48 hr post AI-14-91 treatment.
Furthermore, our findings, although preliminary, demonstrate that RUNX1
inhibition results in an initial decrease in SNAIL2/SLUG expression within the first 12hrs,
followed by an almost 10-fold increase in SNAIL2/SLUG expression at hour 48 (Fig. 27).
Additionally, in AI-14-91-treated MCF10A cells, TWIST1 or ZEB1 expression

Figure 28. RUNX1 inhibition leads to initial repression followed by ~10-fold activation of
SNAIL2/SLUG.
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did not change significantly at any timepoint of treatment, indicating a critical role for
SNAIL2/SLUG in the initiation of breast epithelial cell EMT. Consistent with
SNAIL2/SLUG upregulation, E cadherin protein expression is decreased at hour 48 in AI14-91-treated MCF10A cells (Preliminary) (Fig. 28). However, there is no reciprocal
increase in vimentin signal at this timepoint. We hypothesize that RUNX1 mitotically
bookmarks H2AFX for its activation to prevent SNAIL2/SLUG expression and

Figure 29. Western blot analysis of MCF10A cells treated with either inhibitor for 6, 12, 24, or 48hr
for EMT targets CDH1 and Vimentin. Parental and MDA-MB-231 wells were loaded for maximum
volume, not equal protein loading. 20ug of protein was ran for each inhibitor sample.

subsequently initiate of EMT in breast epithelial cells.

RUNX1 regulation of lncRNAs NEAT1/NEAT2 (MALAT1)
Nuclear enriched abundant transcript 1 (NEAT1) is an important long noncoding RNA (lncRNA) that was identified in our ChIP-Seq data to be mitotically
bookmarked by RUNX1 (data not shown). There is an established role for NEAT1 in
normal mammary gland development and lactation [277]. More recently, NEAT1 role in
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breast cancer progression and tumorigenesis has been demonstrated. Upregulation of
NEAT1, caused by either epigenetic silencing or mutations in BRCA1, causes repression
of miR-129-5p, a downstream target of NEAT1. Decreased levels of miR-129-5p led to
increased WNT4 signaling, which in turn initiates cell proliferation, invasiveness, and
stemness [278]. In a separate study utilizing patient tumor samples, NEAT1 was shown to
be upregulated in breast tumor tissue in comparison to matched normal breast tissue and
this higher expression within tumors correlated with lymph node metastasis and poorer
prognoses in patients [279]. In addition to breast cancer, NEAT1 also has roles in the
formation and progression in a variety of other cancers, demonstrating its potential
importance in tissue development [Reviewed in [257]]. Our ChIP-Seq results show
RUNX1 mitotically bookmarks the TSS and promoter region of NEAT1, potentially
implicating a role in regulating its expression in MCF10A epithelial cells. Although
further studies are necessary, it is plausible that RUNX1 mitotically bookmarks NEAT1,
an oncogene in breast cancer, in MCF10A cells to prevent its expression, thus stabilizing
the mammary epithelial phenotype.

Requirement for mitotic bookmarking of genes in maintenance of an epithelial
phenotype
Our findings are the first to demonstrate mitotic gene bookmarking as an
important mechanism for maintenance of normal mammary epithelial phenotype. Equally
noteworthy, our study shows that disruption of mitotic gene bookmarking specifically
elicits a phenotypic change. Another novel finding of current study is the mitotic
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bookmarking of lncRNAs by a transcription factor. RUNX1 was recently shown to
regulate lncRNAs NEAT1 and NEAT2 (MALAT1) [280], but the mechanism by which
RUNX1 regulates these lncRNAs was not established. Our findings provide the
mechanism for regulation of these lncRNAs in breast epithelial cells. Occupancy of the
Myc enhancer by RUNX1 is another key finding of the current study, with novel
regulatory implications for the onset and progression of breast cancer.
In summary, this work establishes a novel epigenetic mechanism where RUNX1
mitotically bookmarks RNA Pol I and II transcribed genes for coordinate regulation of
normal mammary epithelial proliferation, growth, and phenotype maintenance.
Disruption of RUNX1 bookmarking leads to initiation of epithelial to mesenchymal
transition, a key event in breast cancer onset, and strongly suggests the requirement of
RUNX1 bookmarking for proper maintenance of mammary epithelial phenotype.
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MATERIALS AND METHODS
Cell Culture Techniques
Breast epithelial (MCF10A) cells were cultured in DMEM/F-12 50/50 mixture
(Corning™, Corning, NY). Culturing media was also supplemented with horse serum to
5% (GIBCO, Grand Island, NY), human insulin to 10µg/mL (Sigma Aldrich, St. Louis,
MO), human epidermal growth factor to 20ng/mL (PeproTech, Rocky Hill, NJ), cholera
toxin to 100ng/mL (Thomas Scientific, Swedesboro, NJ), hydrocortisone to 500ng/mL
(Sigma Aldrich, St. Louis, MO), Penicillin-Streptomycin to 100U/mL (Thermo Fisher
Scientific, Ashville, NC), and L-Glutamine to 2mM (Thermo Fisher Scientific, Ashville,
NC).
For mitotic arrest of parental MCF10A cells, culturing media was supplemented
with 50ng/mL of Nocodazole (Sigma Aldrich, St. Louis, MO) and incubated with cells
for 16hrs. Supplementing culturing media with equivalent volumes of DMSO (Sigma
Aldrich, St. Louis, MO) served as a negative control. For DMSO-treated and mitotically
arrested populations of MCF10A cells, harvests were conducted following the 16hr
incubation. For G1 (released from mitotic arrest) populations of MCF10A cells, the
nocodazole-supplemented culturing media was replaced with normal culturing media and
incubated with cells for 3hrs. Following the 3hr incubation, released populations of cells
were harvested for subsequent analysis.
Core binding factor – Beta (CBFβ) inhibitors AI-4-88 and AI-14-91 were given to
us from John H. Bushweller (University of Virginia) and used to evaluate RUNX1
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inhibition in MCF10A cells. Protein synthesis evaluation by immunofluorescence was
conducted following manufacturer protocol (K715-100, BioVision, San Francisco, CA).

Protein Expression and Localization
SDS-PAGE was performed to visualize protein expression within MCF10A cells.
8% SDS resolving gels and 4% stacking gels were prepared in-house (National
Diagnostics, Atlanta, GA). Pelleted cells were resuspended in RIPA buffer and incubated
on ice for 30min. Following incubation, cell lysates were sonicated using Q700 Sonicator
(QSonica, Newtown, CT). Lysates were sonicated using 7 cycles of 10 seconds on/ 30
seconds off at power setting. Lysates were then clarified by centrifugation at 15,000 rpm
for 30min at 4℃. Protein concentration in the remaining supernatant was quantified using
a PierceTM BCA Protein Assay Kit (Thermo Fisher Scientific, Ashville, NC).
Electrophoresis was performed at 160V for 15min followed by 200V for 45min.
Overnight wet transfer of protein into PVDF membranes was performed at 30V for 18hr
in 4℃. PVDF membranes were blocked at room temperature in 5% BSA in 1X TBST.
For protein detection, primary antibodies raised against UBF (sc-13125, Santa Cruz
Biotechnology, Dallas, TX), RUNX1 (4334S, Cell Signaling Technologies, Danvers,
MA), Cyclin B (4138S, Cell Signaling Technologies, Danvers, MA), Beta-Actin (3700S,
Cell Signaling Technologies, Danvers, MA), and CDT1 (ab70829, AbCam, Cambridge,
UK) were used at 1:1000 dilution for western blotting. Lamin B1 (ab16048, AbCam,
Cambridge, UK) was used at 1:2000 dilution for western blotting. Primary antibodies
were diluted in 5% BSA in TBS-T and incubated with blots overnight at 4℃. Blots were
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washed four separate times with PBS-T or TBST. Goat anti-mouse IgG HRP conjugated
(31460, Invitrogen, Carlsbad, CA) secondary antibody was incubated with blots at 1:5000
and incubated for 1hr at room temperature with mild agitation. HRP conjugated goat antirabbit IgG (31430, Thermo Fisher Scientific, Ashville, NC) secondary antibody was
incubated with blots at 1:1000, 1:2000, or 1:5000 and incubated for 1hr at room
temperature with mild agitation. Blots were developed using Clarity Western ECL
Substrate (Bio-Rad, Hercules, CA) following manufacturer’s instructions. Blots were
exposed to visualize protein and images were captured using Molecular Imager® Chemi
docTM XRS+ Imaging System (Bio-Rad, Hercules, CA). Captured images were
processed using Image Lab Software Version 5.1 (Bio-Rad, Hercules, CA).
Immunofluorescent microscopy was performed to observe distribution and
localization of protein expression within MCF10A cells throughout all stages of mitosis
and interphase. MCF10A cells were plated within a 6 well plate at 175,000 cells/mL on
coverslips coated in gelatin (0.5% w/v solution in 1XPBS) and allowed to grow
overnight. Coverslips were washed twice with sterile-filtered PBS at 4℃. Coverslips
were then placed in room temperature fixative solution (1% MeOH-free Formaldehyde in
PBS) for 10min. After a sterile-filtered PBS wash, coverslips were transferred to
permeabilization solution (0.25% Triton X-100 in PBS) for 20min on ice. Following
another sterile-filtered PBS wash, coverslips were then blocked in sterile-filtered PBS
supplemented with bovine serum albumin (PBSA) at 0.5% w/v (Sigma Aldrich, St.
Louis, MO). Coverslips were then incubated with primary antibody for 1hr at 37℃ in a
humidified chamber. Primary antibodies were specific for RUNX1 at a dilution of 1:10
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(4334S, Cell Signaling Technologies, Danvers, MA) and Upstream Binding Transcription
Factor (UBF) at a dilution of 1:200 (F-9 sc-13125, Santa Cruz Biotechnology, Dallas,
TX). Coverslips were washed four separate times in sterile-filtered PBSA following
primary antibody incubation. Coverslips were then placed in secondary antibody for 1hr
at 37℃ within a humidified chamber. Secondary antibodies used were goat anti-rabbit
IgG conjugated with Alexa Fluor 488 (A-11070, Life Technologies, Carlsbad, CA) and
goat anti-mouse IgG conjugated with Alexa Fluor 594 (A-11005, Life Technologies,
Carlsbad, CA) diluted 1:800. Coverslips were then washed four times in sterile-filtered
PBSA. Staining of the coverslips for DNA was performed with 1.0µg DAPI in 0.1%
Triton X-100 and sterile-filtered PBSA for 5min on ice. Stained coverslips were washed
once in 0.1% Triton X-100 in sterile-filtered PBSA, then two times with sterile filtered
PBS. Coverslips were mounted onto slides using ProLong Gold Antifade Mountant
(Thermo Fisher Scientific, Ashville, NC). Images were captured using a Zeiss Axio
Imager.Z2 fluorescent microscope and Hamamatsu ORCA-R2 C10600 digital camera.
Images were processed using ZEN 2012 software.
Confocal microscopy was performed on slides prepared as described above.
MCF10A breast epithelial cells were initially imaged with a Zeiss LSM 510 META
confocal laser scanning microscope (Carl Zeiss Microscopy, LLC., Thornwood, NY,
USA) for a preliminary study to assess potential colocalization.

At a later time,

additional samples were imaged with a Nikon A1R-ER laser scanning confocal
microscope (Nikon, Melville, NY, USA) for complete colocalization analysis. Images
were acquired with the resonant scanner at a frame size of 1024 X 1024 pixels with 8X
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averaging. Fluorescently labeled samples were excited by laser lines sequentially imaged
in channel series mode. The DAPI signal was excited with a 405 nm laser and collected
with a 425-475 nm band pass filter, Alexa 488 was excited with a 488 nm laser and
collected with a 500-550 nm band pass filter, and Alexa 568 with a 561 nm laser and
collected with a 570-620 nm band pass filter. Images were captured with a Plan-Fluor
40X (1.3 NA) objective lens. The confocal pinhole was initially set to 1.2 Airy Unit
diameter for the 561 nm excitation giving an optical section thickness of 0.41 µm. Images
were acquired at 12-bit data depth, and all settings, including laser power, amplifier gain,
and amplifier offset were established using a look-up table to provide an optimal grayscale intensity. All images were acquired using matching imaging parameters.
Images were acquired with at 40X objective were subject to colocalization
analysis via Volocity version 6.3.0 (Perkin Elmer, Waltham, MA, USA). Images were
opened in the colocalization tab. Cell nuclei, indicated by the DAPI signal, were circled
via the ROI tool. At least 15 interphase and 15 metaphase cells were identified within
captured images and appropriate thresholds were manually determined to eliminate
background fluorescence for calculating Pearsons and Manders correlation coefficients
between RUNX1 and UBF.
Images were also viewed in NIS Elements version 5.02.01 and analyzed using the
line profiling tool. Overlaying DAPI, RUNX1, and UBF fluorescent intensities from
individual channels along the line profile revealed overlapping peak intensities between
the RUNX1 and UBF channels, thus indicating colocalization.
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Molecular Techniques and Sequencing/Bioinformatics
Total RNA was isolated from MCF10A cells using TRIzolTM Reagent
(Invitrogen, Carlsbad, CA) and Direct-ZolTM RNA MiniPrep isolation kit (Zymo
Research, Irvine, CA) following manufacturer instructions. cDNA was created using
SuperScript IV® First-Strand Synthesis System for RT-PCR (ThermoFisher, Asheville,
NC). Resulting cDNA were quantified on a Qubit 2.0 Fluorometer (Invitrogen, Carlsbad,
CA) and diluted to 500pg/μL. Equal amounts of DNA template were loaded for samples
analyzed by qPCR.
Chromatin Immunoprecipitation was conducted on asynchronous (Asynch),
mitotically arrested (M), and released from mitosis (G1) MCF10A breast epithelial cells.
Cells were fixed with 1% v/v MeOH-free Formaldehyde in PBS for 10min at room
temperature. Formaldehyde fixation was neutralized using 2.5M Glycine and incubated
with cells for 5min at room temperature. Two washes with PBS supplemented with
cOmpleteTM EDTA-free Protease Inhibitor Cocktail (Sigma Aldrich, Saint Louis, MO)
and MG-132 (Calbiochem-Millipore Sigma, Burlington, MA) were performed. For
asynchronous and G1 populations of cells, culture dishes were scraped to collect fixated
lysate. Mitotic cells were isolated using a mitotic shake off. Mitotic cells were spun down
at 1500rpm x 5min, resuspended in 1% v/v MeOH-free Formaldehyde in PBS, and
neutralized with 2.5M Glycine for 5min. Fixed harvests were centrifuged at 1500rpm x
5min (4oC) and the supernatant was discarded. All fixed cell pellets were flash frozen in
liquid nitrogen and stored at -80oC until lysis.
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Fixed cell pellets were thawed on ice. Once thawed, pellets were lysed in a
nuclear lysis buffer supplemented with cOmpleteTM EDTA-free Protease Inhibitor
Cocktail (Sigma Aldrich, Saint Louis, MO) and MG-132 (Calbiochem-Millipore Sigma,
Burlington, MA) with a volume that was approximately 5X the volume of pellet. Pellets
were incubated in nuclear lysis buffer for 30min before being flash frozen down in liquid
nitrogen. Lysates were thawed at room temperature but not allowed to reach room
temperature. Sonication of the lysates were performed using a S220 focused ultrasonicator (Covaris, Matthews, NC). Sonication parameters for each population of cells
was as follows: Peak Watt 140W, Duty Factor 10, Cycle/Burst 200. M and G1
populations of cells were sonicated for 28min total whereas asynchronous populations of
cells were sonicated for 36min. All samples were sonicated at 6oC. Following sonication,
aliquots were spun down at 15,000rpm x 10min and 4oC. Following the spin, the
resulting supernatants were pooled together and analyzed.
Sonicated lysate was boiled in 100oC for 15min with NaCl and elution buffer.
Boiled lysate was allowed to cool and treated with RNaseA (10ug/uL) for 10min at 37 oC.
DNA was isolated using PureLinkTM PCR Purification Kit (K310001, ThermoFisher,
Ashville, NC) following manufacturer recommendations. Resulting DNA was quantified
via nanodrop and 1-2μg was separated on a 1.5% agarose gel to observe relative fragment
size distribution prior to generating ChIP reactions. Resulting DNA was also quantified
via Qubit 2.0 Fluorometer (Invitrogen, Carlsbad, CA) and analyzed by using a High
Sensitivity DNA Kit on a Bioanalyzer 2100 (Agilent, Santa Clara, CA).
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For chromatin immunoprecipitation (ChIP) reactions, 150μg of sonicated
chromatin was incubated with 10μg of RUNX1 antibody (4336BF, Cell Signaling
Technologies, Danvers, MA), diluted 1:10 in IP dilution buffer, and incubated overnight
(16-18hrs) at 4oC with mild agitation. Following incubation, 150μL of Protein A/G
magnetic beads (Thermo Scientific – Pierce, Waltham, MA) per ug of antibody used
were added to each IP reaction and incubated for 2-4hrs at 4oC with mild agitation. Beads
were isolated from solution using a neodymium magnet separator and washed two times
in two separate IP wash buffers. Lastly, beads were resuspended in an elution buffer and
agitated in a thermomixer (Eppendorf, Hamburg, Germany) or vortexer at 1000rpm x
30min at room temperature. This elution step was repeated on the beads, beads discarded,
and the resulting supernatant was incubated with NaCl overnight (16-18hrs) at 67oC to
reverse formaldehyde crosslinks. DNA from RUNX1 ChIP samples were purified using
PureLinkTM PCR Purification Kit (K310001, ThermoFisher, Ashville, NC) following
manufacturer recommendations.
DNA libraries were generated using Accel-NGS® 2S Plus DNA Library kit
(Swift Biosciences, Ann Arbor, MI) following manufacturers protocol. Input and
RUNX1 ChIP samples were normalized to 1ng prior to library generation. Libraries were
amplified in an optional PCR step for 12 total cycles. Finalized libraries were double size
selected using AMPure XP beads (0.8X and 0.2X volume ratios to sample), resulting in
the majority fragments sized between 250-400bp. Next generation sequencing of pooled
ChIP libraries was performed by the University of Vermont Cancer Center - Vermont
Integrated Genomics Resource (VIGR).
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Because we were specifically investigating rDNA, a customized build of hg38
was constructed that included normally masked regions of rDNA (Gencode U13369).
Since some (although not complete) rDNA sequence is present in the hg38 assembly, we
masked all parts of hg38 that would normally be attributed to rDNA sequences (bedtools
v2.25.0 maskfasta).

Finally, we appended the rDNA sequence as a “unique”

chromosome (chrU13369.1) to the masked hg38 fasta resulting in the hg38_rDNA
assembly used for analysis.
Single-end, SE50 reads were processed pre-alignment by removing adapter reads
(Cutadapt v1.6) and trimming low quality base calls from both ends (FASTQ Quality
Trimmer 1.0.0; min score >= 20, window of 10, and step size of 1). Resulting reads were
aligned to hg38_rDNA (STAR v2.4; splicing disabled with '--alignIntronMax 1'). Peaks
were called and fold-enrichment (FE) bedGraph files were generated (MACS2
v2.1.0.20140616; callpeak at p-value e-5; and bdgcmp with FE method) [247].
Irreproducible Discovery Rate (IDR) was conducted using unpooled replicates with all
peaks in pooled samples passing an IDR cutoff of 0.5 [281]. To reduce artificial peaks,
we calculated strand cross-correlation for all peaks at a shift of 95 bp (the mean observed
fragment size of 180 bp minus the read size of 85 bp) and unshifted [124].

We

eliminated peaks that exhibited low shifted correlation (shifted correlation <.7) and those
that exhibited high unshifted correlation relative to shifted (shifted – unshifted correlation
< .1). This increased retrieval of the RUNX1 motif and improved agreement with other
RUNX1 datasets. Passing peaks were annotated separately to mRNA and lncRNA
transcript start sites (TSSs) using GENCODE v27 with a distance cutoff of 5000 bp.
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Regional distribution of peaks was determined using the same annotation reference
limited to the “basic” tag for exons and promoters.
SUPPLEMENTAL MATERIAL
Table 1. RUNX1 mitotically bookmarked genes in MCF10A breast epithelial cells. (N=417 total)
gene_name
HSPB6
HCCS
KMT2E
MYCBP2
TNFRSF12A
KDM7A
ETV1
ALDH3B1
CDK11A
SYPL1
SPAG9
CRY1
CSDE1
AKAP8L
MATR3
WWTR1
ZNF839
RTEL1-TNFRSF6B
SH3YL1
MAT2B
CLEC16A
HSPA5
TPR
POLR3E
ATP2B4
PRDM6
SPAG4
MRPS24
WISP2
CNN2
SBNO2
KARS
PPP2R5A
KLF6
TP53BP1
DHX8
COASY
PRR11
ASNS
OSBPL3
ALDH3A2
FSCN1
REXO2
ARHGEF1
NFKB2
FAM76B
CARMIL1
CNOT4
EXD2
FAM135A

gene_id
ENSG00000004776
ENSG00000004961
ENSG00000005483
ENSG00000005810
ENSG00000006327
ENSG00000006459
ENSG00000006468
ENSG00000006534
ENSG00000008128
ENSG00000008282
ENSG00000008294
ENSG00000008405
ENSG00000009307
ENSG00000011243
ENSG00000015479
ENSG00000018408
ENSG00000022976
ENSG00000026036
ENSG00000035115
ENSG00000038274
ENSG00000038532
ENSG00000044574
ENSG00000047410
ENSG00000058600
ENSG00000058668
ENSG00000061455
ENSG00000061656
ENSG00000062582
ENSG00000064205
ENSG00000064666
ENSG00000064932
ENSG00000065427
ENSG00000066027
ENSG00000067082
ENSG00000067369
ENSG00000067596
ENSG00000068120
ENSG00000068489
ENSG00000070669
ENSG00000070882
ENSG00000072210
ENSG00000075618
ENSG00000076043
ENSG00000076928
ENSG00000077150
ENSG00000077458
ENSG00000079691
ENSG00000080802
ENSG00000081177
ENSG00000082269

gene_type
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding
protein_coding

seqnames
chr19
chrX
chr7
chr13
chr16
chr7
chr7
chr11
chr1
chr7
chr17
chr12
chr1
chr19
chr5
chr3
chr14
chr20
chr2
chr5
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ENSG00000172927
ENSG00000172932
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ENSG00000176532
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ENSG00000178449
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protein_coding
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chr8
chr7
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chr7
chr9
chr9
chr14
chr11
chr16
chr10
chr16
chr16
chr16
chr15
chr19
chr19
chr19
chr12
chr17
chr16
chr11
chr11
chr1
chr7
chr3
chr8
chr16
chr2
chr1
chr5
chr15
chr8
chr8
chr16
chr2
chr11
chr16
chr22
chr8
chr5
chr10
chr11
chr16
chr11
chr11
chr1
chr2
chr14
chr3
chr7
chr11
chr19
chr7
chr19
chr7
chr2
chr22
chr12
chr8
chr15

86

77001044
1560821
151058530
151057210
15422704
15511019
74493720
95789965
46884378
101354033
66925644
66934423
75647786
43510958
35758143
5680604
52690496
52192000
76868456
2252300
61967660
62856102
234373456
40134659
57598220
38996869
67227103
227325151
155209051
148825245
75455842
141002216
38996824
30194306
110678114
130002835
18801678
50185915
124474738
113488830
73782047
67317871
66934444
69294138
67288547
155208699
61177418
20609884
47782106
75092573
66336840
5680896
40134977
39540333
29563811
135047468
42074251
50111979
144078626
41230743

77001044
1560821
151058530
151057210
15422704
15511019
74493720
95789965
46884378
101354033
66925644
66934423
75647786
43510958
35758143
5680604
52690496
52192000
76868456
2252300
61967660
62856102
234373456
40134659
57598220
38996869
67227103
227325151
155209051
148825245
75455842
141002216
38996824
30194306
110678114
130002835
18801678
50185915
124474738
113488830
73782047
67317871
66934444
69294138
67288547
155208699
61177418
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47782106
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+
+
+
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+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-

522
4432
0
1019
0
0
105
0
375
0
1331
0
0
0
0
0
0
74
3904
401
456
0
0
0
1363
102
0
0
0
3130
4084
0
57
313
0
569
0
4343
0
435
0
0
0
3087
0
185
195
3484
0
408
0
0
46
0
900
4907
3226
0
0
104

PER1
SPTY2D1
SHARPIN
HTR1D
MAF1
WDR97
ZNRF2
KCTD2
RAP2B
MRPS23
DEXI
MOB2
FBXL6
SKA2
C16orf72
NPIPA1
UPP1
ELOA3
GPR39
TMEM173
CLDN6
PRMT3
SLC52A2
DYNC2H1
CHP1
SCGB1C1
H2AFX
UTS2B
LIN54
SRGAP3
CD55
FAM72A
MKL1
STRN3
LAMB3
FBXL22
STMN3
RPE
ZNF181
GPAA1
AC092143.1
HYLS1
NAGA
PJA2
MRPL38
SCGB2B2
FGFR1OP
COG8
ZSWIM8
AC078927.1
TMEM238
TRIM26
JRK
CHMP1B
AC106782.1
RTEL1
TUBB3
AL163195.3
AC138811.2
AC010542.3
TMEM249
GAN
OTUD7B
ANXA8
SRGAP2
AC008403.1
FAM231B
AC008750.8
HIST2H4A
NBPF19
AC233992.2
KMT2B
COG8
NBPF26
HIST1H4E
HIST1H4D
ELOA3B
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ENSG00000265190
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ENSG00000272333
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ENSG00000277157
ENSG00000278674
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chr17
chr11
chr8
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chr8
chr8
chr7
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chr17
chr16
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chr16
chr11
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chr11
chr15
chr11
chr11
chr3
chr4
chr3
chr1
chr1
chr22
chr14
chr1
chr15
chr20
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chr19
chr8
chr16
chr11
chr22
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chr17
chr19
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chr16
chr10
chr12
chr19
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chr18
chr16
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chr16
chr14
chr16
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chr19
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chr1
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8156506
18634791
144108124
23194729
144104499
144107726
30284307
75032575
153162270
57850056
10942460
1501247
144359376
59155269
9091648
14922802
48088628
47030078
132416574
139482935
3020071
20387530
144354135
103109431
41230839
193080
119095467
191330536
83012926
9363053
207321508
206204414
40636702
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209652466
63597353
63657682
210002565
34734155
144082590
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125883614
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69339583
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66169985
55384598
30213427
142681968
11851396
30209071
63657810
89921392
20609795
18801519
66517312
144354914
81314952
150010676
47484158
206203345
48465837
16539066
51368099
149832659
149390623
144355609
35718019
69339667
120723923
26204552
26189076
47023927

8156506
18634791
144108124
23194729
144104499
144107726
30284307
75032575
153162270
57850056
10942460
1501247
144359376
59155269
9091648
14922802
48088628
47030078
132416574
139482935
3020071
20387530
144354135
103109431
41230839
193080
119095467
191330536
83012926
9363053
207321508
206204414
40636702
31026401
209652466
63597353
63657682
210002565
34734155
144082590
89919165
125883614
42070842
109409994
75905413
34675699
166999182
69339583
73785582
66169985
55384598
30213427
142681968
11851396
30209071
63657810
89921392
20609795
18801519
66517312
144354914
81314952
150010676
47484158
206203345
48465837
16539066
51368099
149832659
149390623
144355609
35718019
69339667
120723923
26204552
26189076
47023927

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-

1758
572
2714
2124
410
2316
1632
1733
503
0
1661
1644
271
0
182
1161
335
1279
0
314
866
0
4469
0
8
3061
0
980
9
0
0
2371
43
361
4570
4054
582
0
0
3780
808
3770
0
211
4034
1642
1076
0
3231
0
182
598
4548
973
3906
454
3035
3573
0
73
3690
0
0
2237
1302
2831
2871
0
0
0
2995
506
0
0
546
0
990

Table 2. RUNX1 bookmarked genes that are bound by ER and are differentially expressed (either up
or down) upon estrogen treatment.
gene_id
ENSG00000006534
ENSG00000064932
ENSG00000104957
ENSG00000105856
ENSG00000114315
ENSG00000126461
ENSG00000130649
ENSG00000131652
ENSG00000137312
ENSG00000149043
ENSG00000156453
ENSG00000164070
ENSG00000172927
ENSG00000189308
ENSG00000276966

gene_name
ALDH3B1
SBNO2
CCDC130
HBP1
HES1
SCAF1
CYP2E1
THOC6
FLOT1
SYT8
PCDH1
HSPA4L
MYEOV
LIN54
HIST1H4E

baseMean
223.764483
821.5236174
225.5108634
1707.02922
1118.247038
594.8761924
23.32770091
443.1523134
891.4108791
37.01811475
647.6693707
206.0022589
31.07297255
514.9465205
1563.433919

log2FoldChange
-1.486043549
0.418847935
-0.47886552
-0.792170507
-1.062455094
0.523342397
-1.011494498
0.327922269
-0.542205658
1.381161412
-0.813604616
0.942744258
2.202080169
0.520387566
1.181840259

lfcSE
0.292189004
0.157636559
0.178215127
0.180235367
0.183071692
0.167935604
0.315636584
0.125154411
0.207900051
0.345434679
0.200521252
0.248477038
0.346033148
0.186238281
0.199327077

88

stat
5.085898274
-2.657048196
2.68700827
4.39520012
5.803491963
-3.116327838
3.204617426
-2.620141511
2.608011185
-3.998328756
4.057448322
-3.794090052
-6.363783884
-2.794203008
-5.929150602

pvalue
3.66E-07
0.007882817
0.007209517
1.11E-05
6.49E-09
0.001831186
0.001352421
0.008789329
0.009106998
6.38E-05
4.96E-05
0.000148186
1.97E-10
0.005202781
3.05E-09

padj
1.37E-05
0.043159725
0.040327755
0.0002326
4.68E-07
0.014261354
0.011202425
0.046980735
0.048334548
0.001007558
0.000815465
0.001948169
2.44E-08
0.031446101
2.39E-07

binding
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1
ESR1+RUNX1

group
RUNX1 Bookmarked
bound, de Down
yes
bound, de Up
yes
bound, de Down
yes
bound, de Down
yes
bound, de Down
yes
bound, de Up
yes
bound, de Down
yes
bound, de Up
yes
bound, de Down
yes
bound, de Up
yes
bound, de Down
yes
bound, de Up
yes
bound, de Up
yes
bound, de Up
yes
bound, de Up
yes
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